Drug, bio-affecting and body treating compositions inventions 10/08

20080261861 - 2-micron family plasmid and use thereof: The present invention provides a 2 μm-family plasmid comprising a polynucleotide sequence insertion, deletion and/or substitution between the first base after the last functional codon of at least one of either a REP2 gene or an FLP gene and the last base before the FRT site in an inverted repeat... Agent: Synnestvedt & Lechner, LLP

20080261862 - Materials and methods for modulating signalling by alpha-v integring molecules: It is disclosed that the αvβ5 integrin mediates the proliferative signal provided by CD23 to pre-B cells. The region of CD23 which interacts with αvβ5 has been defined, and found to interact with a site on the integrin distinct from that which binds RGD. The invention provides methods for disrupting... Agent: Dann, Dorfman, Herrell & Skillman

20080261864 - Combination of nateglinide or repaglinide with at least one further antidiabetic compound: The present invention relates to a combination of organic compounds which comprises at least two antidiabetic agents, preferably with different modes of action, in which the active ingredients are in each case present in free form or in the form of a pharmaceutically acceptable salt and, optionally, at least on... Agent: Novartis Corporate Intellectual Property

20080261863 - Pegylation of vasoactive intestinal peptide (vip) / pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use: This invention relates to modified Vasoactive Intestinal Peptide (VIP)/Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor 2 (VPAC2) agonists (VPAC2 agonists) comprising a VPAC2 agonist linked to a polyethylene glycol polymer, as well as related formulations, dosages, and methods of administration thereof for therapeutic purposes. These VPAC2 agonists, compositions, and methods... Agent: Barbara A. Shimei Director, Patents & Licensing

20080261869 - Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity: Embodiments herein illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating a bacterial infection, or a viral infection in a subject. More particularly, embodiments herein relate to compounds including naturally occurring and synthetic compositions having alpha-1 antitrypsin activity but... Agent: Faegre & Benson LLP Patent Docketing

20080261866 - Compositions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug: Pharmaceutical compositions comprising of glycosaminoglycan or salts thereof, preferably chondroitin or salts thereof, more preferably chondroitin sulphate, and nonsteroidal anti-inflammatory drug(s) or salts thereof, optionally with pharmaceutically acceptable excipient(s) are described. The compositions of the present invention provide gastrosparing effect in conditions where nonsteroidal anti-inflammatory drug(s) or their salts are... Agent: Ladas & Parry LLP

20080261868 - Methods and compositions for treating diabetes: The instant invention provides a method of treating an animal suffering a disease characterized by excessive apoptosis by administering a therapeutically effective amount of at least one serine protease inhibitor and thereafter monitoring a decrease in apoptosis. The inhibitor of the invention includes α1-antitrypsin or an α1-antitrypsin-like agent, including, but... Agent: Don D. Cha

20080261865 - Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20080261867 - Soluble inhibitors of vascular endothelial growth factor and use thereof: The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with... Agent: David S. Resnick

20080261877 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080261888 - Antibodies to pdgf-d: PDGF-D, a new member of the PDGF/VEGF family of growth factors, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications, including methods... Agent: Fulbright & Jaworski, LLP

20080261873 - Growth-hormone secretagogues: Disclosed are methods of treating a disorder of the stomach, intestine or duodenum in a human subject. The method includes administering to the subject, a pharmaceutical composition comprising a compound that increases gastrointestinal motility (e.g., by modulating myenteric nerve activity) and/or induces the secretion or production of growth hormone.... Agent: Fish & Richardson PC

20080261884 - Lung volume reduction therapy using crosslinked biopolymers: One aspect of the present invention relates to bronchoscopic lung volume reduction using solutions of biopolymers that can be polymerized in situ with a crosslinker and a polymeric additive which accelerates the cross-linking reaction. In certain embodiments, the biopolymer solutions can be in the form of a foam or gel.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080261879 - Method of inducing and maintaining neuronal cells: The present invention makes available a method for inducing neuronal differentiation and preventing the death or degeneration of neuronal cells both in vitro and in vivo. The subject method stems from the unexpected finding that, contrary to traditional understanding of neural induction, the default fate of ectodermal tissue is neuronal... Agent: Ropes & Gray LLP

20080261889 - Method for determining the risk of developing a neurological disease: Methods and kits are provided for determining whether a subject is at risk of developing a neurological disease such as Alzheimer's disease and multiple sclerosis. The methods and kits are based on the detection of one or more nucleic acid variants in the MBL gene of the subject.... Agent: Howrey LLP-hn

20080261876 - Method for purifying marine collagen and the processing thereof into porous sponges: Methods are provided for purifying marine collagen and for processing the collagen into porous sponges. Products produced with these methods and the use of the products are also provided.... Agent: Panitch Schwarze Belisario & Nadel LLP

20080261875 - Method for treating cardiovascular disease: A method for treating cardiovascular disease comprising administering an effective amount of FGF-21 or an FGF-21 compound to a patient in need thereof.... Agent: Eli Lilly & Company

20080261878 - Method of inducing the formation of neurofibrillary tangles in transgenic animals: The present invention discloses a method and an in-vivo assay system useful for the identification and testing of modulating agents as well as for the validation of therapies of neurodegenerative diseases associated with the formation of neurofibrillary tangles, in particular Alzheimer's disease. The present invention is based on the surprising-finding... Agent: Jacobson Holman PLLC

20080261882 - Methods for inhibiting heregulin and treating cancer: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to... Agent: Cohen & Grigsby, P.C.

20080261874 - Mutants of trichosanthin with anti-tumor activity and lowered side-effects: The invention provides the mutants and coding genes of trichosanthin (TCS). The mutants thereof are the TCS mutants with the single or double alternation of tyrosine-55 and aspartate-78 (counted from N-terminus), wherein the tyrosine-55 is mutated to an aliphatic amino acid and aspartate-78 is mutated to an amino acid with... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20080261885 - Process for the extraction, purification and enzymatic modification of soy 7s globulin alpha' subunit for use as hypocholesterolemizing agent: A process for the extraction, purification and enzymatic modification of β-conglycinin α′ subunit, wherein β-conglycinin is selectively extracted from ground, defatted soy, then precipitated by treatment with aqueous ethanol; the enriched fraction is then subjected to Metal Affinity Chromatography (MAC) in denaturant conditions to obtain the α′ subunit, which is... Agent: Young & Thompson

20080261883 - Runx3 gene showing anti-tumor activity and use thereof: The present invention relates to a RUNX3 gene showing anti-tumor activity which is essentially involved in TGF-β-dependent programmed cell death (apoptosis) and use thereof. In addition, the present invention finds that RUNX3 gene expression is suppressed in the various gastric cancer and lung cancer cell lines. The suppression of the... Agent: Lucas & Mercanti, LLP

20080261886 - Single-dose administration of factor viia: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080261880 - Synthetic approach to designed chemical structures: This invention relates to the chemical design and production of peptides, peptide structure and three dimensional conformation was assessed using NMR, circular dichroisin and pulsed field gradient NMR. In addition, this invention relates to peptides produced by these methods and to methods for using the peptides.... Agent: Mueting, Raasch & Gebhardt, P.A.

20080261887 - Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080261872 - Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions: A novel combination of ghrelin and unacylated ghrelin is described herein. Methods of administering and uses of this combination to alter an insulin-associated parameter are also described. Compositions and packages containing ghrelin and/or one of its analogs and nonacylated ghrelin and/or one of its analogs as well as the uses... Agent: Wilmerhale/boston

20080261881 - Use of human chorionic gonadotropin (hcg) orally or for injection for the treatment of mood disorders and alcoholism: n

20080261890 - Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions: The invention further features novel methods and compositions for treating and preventing dry eye by administration of neurotransmitters and/or neuropeptides, optionally in formulation with various other agents, as well as kits for the use of such novel formulations and methods.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080261870 - Use of the pro-peptide domain of lysyl oxidase as a therapeutic agent: A therapeutic composition that includes an active portion of the lysyl oxidase pro-peptide in a pharmaceutically acceptable carrier substance and methods of using such a therapeutic composition are disclosed. The active agent does not have lysyl oxidase enzymatic activity. Preferably, the active polypeptide is active in inhibiting cell growth in... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20080261871 - Y2/y4 selective receptor agonists for therapeutic interventions: Y receptor agonists which are selective for Y2 and Y4 receptors over the Y1 receptor are useful for treatment of, for example obesity, are (a) PP-fold peptides or PP-fold peptides mimics which have (i) a C-terminal Y receptor-recognition amino acid sequence represented by —X-Thr-Arg-X3-Arg-Tyr-C(=0)NR1R2 wherein R1 and R1 are independently... Agent: Banner & Witcoff, Ltd.

20080261891 - Compositions and methods for using syringopeptin 25a and rhamnolipids: The present invention provides a therapeutic composition having at least one syringopeptin and at least one rhamnolipid so that the composition has one or more of the following activities: antibacterial; antifungal; and antitumor activity. The therapeutic composition includes the following: a therapeutically effective amount of a syringopeptin; a therapeutically effective... Agent: Utah State University/workman Nydegger

20080261892 - Acid addition salts of ac-phscn-nh2: Acid addition salts of Ac—PHSCN—NH2, methods of making acid addition salts of Ac—PHSCN—NH2, pharmaceutical compositions of acid addition salts of Ac—PHSCN—NH2, methods of using acid addition salts of Ac—PHSCN—NH2 and pharmaceutical compositions thereof to treat diseases associated with angiogenesis and aberrant vascularization and methods of preventing degradation of Ac—PHSCN—NH2 by... Agent: Jones Day

20080261893 - Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing: A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg alternatively about 0.0001 to about 3... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-1118

20080261894 - Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis: The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a... Agent: Cooper & Dunham, LLP

20080261898 - Composition and method for cancer treatment and prevention: Compounds, compositions, methods and kits are provided for treating, reducing the risk of, or preventing diseases and/or conditions, such as diseases associated with angiogenesis and/or abnormal cell proliferation, such as cancer. Compounds of the present invention have antiangiogenic and anti-cancer activity with minimum toxic effects on normal cells. Methods for... Agent: Wilson Sonsini Goodrich & Rosati

20080261897 - Formulation containing a polyphenol-containing composition and isomaltulose: The present invention relates to formulations containing isomaltulose and a polyphenol-containing composition, uses of same and the use of isomaltulose for masking unwanted taste components, in particular bitter substances, in formulations, in particular in formulations containing tea extracts.... Agent: Ostrolenk Faber Gerb & Soffen

20080261895 - Isolated hydroxy and n-oxide metabolites and derivatives of o-desmethylvenlafaxine and methods of treatment: The present invention provides novel isolated compounds characterized as metabolites or derivatives of desmethylvenlafaxine including hydroxy-DV metabolites, hydroxy-DV-glucuronide metabolites, N-oxide-DV metabolites, and benzyl-hydroxy-DV metabolites. The invention includes pharmaceutical compositions comprising any of the metabolites or derivatives of the invention in combination with a pharmaceutically acceptable carrier or excipient. The invention... Agent: Wyeth/finnegan Henderson, LLP

20080261896 - Testosterone generating and metabolizing enhancer: A testosterone generating and metabolizing enhancer is proposed in the invention, which increases concentrations of testosterone in both seminal vesicle and bloodstream, and may further promote the gene expression of metabolizing testosterone into 5α-reductase of dihydrotestosterone. The testosterone generating and metabolizing enhancer of the invention is characterized in that an... Agent: Bacon & Thomas, PLLC

20080261899 - Agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component: The present invention relates to an agent for controlling Bcl-2 expression comprising ginsenoside F1 (20-O-β-D-glucopyranosyl-20(S)-protopanaxatriol) represented by the following formula 1 as an active component.... Agent: Sughrue Mion, PLLC

20080261900 - Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria: Compositions comprise a fluoroquinolone having Formulae I-VIII for treating, reducing, ameliorating, or preventing infections caused by some bacteria that are resistant to an antibacterial drug. Methods for treating, reducing, ameliorating, or preventing such infections use such compositions.... Agent: Bausch & Lomb Incorporated

20080261901 - Cosmetic composition comprising beta-fructosyl-l-ascorbic acid for skin whitening: The present invention is related to novel cosmetic composition comprising β-fructosyl-L-ascorbic acid derivatives produced by fructose conversion reaction using by ascorbic acid and the compounds shows potent inhibiting effect on the activity of tyrosinase enzyme, therefore, it can be useful as a skin whitening cosmetic composition as an cream, skin,... Agent: Kirk Hahn

20080261902 - Pharmaceutical composition containing polydatin and its application: A composition includes polydatin and solvent for dissolving the polydatin, wherein the solvent comprises alcohol in a range between 40 and 95% by volume, propanediol in a range between 0 and 60% by volume, and water in remaining volume. The concentration of the polydatin must be at least 6 mg/ml.... Agent: David And Raymond Patent Firm

20080261912 - Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same: Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.... Agent: Marina Larson & Associates, LLC

20080261904 - Chimeric gapped oligomeric compounds: The present invention provides double stranded compositions wherein the first strand comprises three different regions and the second strand is native RNA. Each region has native or modified ribofuranosyl sugar moieties that are different than those of the other two regions. At least a portion of the first oligomeric compound... Agent: Woodcock Washburn LLP

20080261907 - Compositions and methods of sphingosine kinase inhibitors in radiation therapy of various cancers: The present invention relates to Sphingosine kinase inhibitors that are useful for treating various cancers. The invention further relates to compositions and methods of SPK inhibitors, including siRNAs, which specifically block gene expression of SPK and potentiates the effect of radiation in the treatment of various cancers.... Agent: Hogan & Hartson L.L.P.

20080261910 - Diagnostic methods based on polymorphisms of glucosyltransferase-like protein: The present invention arises from the identification of an association between the gene encoding glucosyltransferase-like protein (GT) and osteoarthritis (OA). It therefore relates to diagnostic techniques for determining a patient's susceptibility to develop OA by detecting all or part of the GT gene, its precursors or products (mRNA, cDNA, genomic... Agent: Fish & Richardson P.C.

20080261909 - Gene delivery to organs: Application of a virus with poloxamer alone onto atria results in diffuse epicardial gene transfer with negligible penetration into the myocardium. Progressive increases in protease concentration, however, allow transmural gene transfer. After protease exposure, echocardiographic left atrial diameter does not change. Left atrial ejection fraction decreases on post-operative day 3,... Agent: Banner & Witcoff, Ltd.

20080261906 - Methods and compositions for identifying anti-hcv agents: The invention features methods and compositions for screening for agents that modulate replication of a virus, particularly Flaviviridae virus (particularly hepatitis C virus (HCV)), where the methods provide for detection of agents that modulate the binding of TBC and NS5A, the inhibition of TBC activity, inhibition of Rab1 activity, and/or... Agent: Bozicevic, Field & Francis LLP

20080261908 - Microrna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer: The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of breast cancer. The invention also provides methods of identifying anti-breast cancer agents.... Agent: Macmillan Sobanski & Todd, LLC

20080261905 - Modified nucleosides for rna interference: The present invention relates to the use of modified nucleotides and single or double stranded oligonucleotides having at least one of said modified nucleotides for performing RNA interference. The modified nucleotides are selected from 6-membered ring containing nucleotides such as hexitol, altritol, O-substituted or O-alkylated altritol, cyclohexenyl, ribo-cyclohexenyl and O-substituted... Agent: Knobbe Martens Olson & Bear LLP

20080261903 - Regulation of kinase, regulated in copd kinase (rc kinase): Reagents which regulate human RC Kinase activity and reagents which bind to human RC Kinase gene products can be used to regulate this protein for therapeutic effects. Such regulation is particularly useful for treating chronic obstructive pulmonary disease, asthma, cancer, and diseases in which cell signaling is defective.... Agent: Jones Day

20080261911 - Uses of diphenyl/diphenylamine carboxylic acids: The present invention demonstrates that chemical-induced degradation of Sp proteins by a specific sub-class of non-steroidal anti-inflammatory drugs inhibited cancer cell growth, angiogenesis and metastasis of cancer cells. The inhibitory effects of these compounds were demonstrated in vitro and in vivo. Hence, the results discussed herein indicate that these compounds... Agent: Benjamin Aaron Adler Adler & Associates

20080261913 - Compounds and pharmaceutical compositions for the treatment of liver disorders: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including liver cancer and metabolic diseases, such as diabetes, hyperlipidemia, atherosclerosis, and obesity. Specifically, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents.... Agent: Jones Day

20080261914 - Stabilization of vitamin b12: The invention relates to preparations comprising vitamin B12 and a butanol, and to the use of butanol for stabilizing vitamins.... Agent: Bayer Healthcare LLC

20080261915 - Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate: This invention relates to wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate.... Agent: Steinfl & Bruno

20080261916 - Synergistic prebiotic compositions: The invention relates to synergistic compositions comprising prebiotic components selected from fructose polymers GFn and Fm, either containing a glucose (G) end-group, or without a glucose end-group, and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed inulin,... Agent: Hahn & Voight PLLC

20080261920 - 2-aminooxazolines as taar1 ligands: X, Y, R1, R2, and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080261919 - Camptothecin-analog with a novel, \"flipped\" lactone-stable, e-ring and methods for making and using same: The present invention discloses: (i) a novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (iii) pharmaceutically-acceptable formulations comprising said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one... Agent: Scott A. Whitaker, Ph.d., J.d. - Sr. Intellectual Property Counsel

20080261917 - Isoindolin-1-one derivatives: or a prodrug and/or a pharmaceutically acceptable salt thereof, wherein X is O, N or S; R1 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; R2 is hydrogen,... Agent: Notaro And Michalos

20080261918 - Silicon compounds and their use: A compound of any of formulas (I) to (V): wherein at least one of Y and Z includes a Si atom, is of utility in therapy.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080261921 - Fused ring heterocycle kinase modulators: The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.... Agent: Wilson Sonsini Goodrich & Rosati

20080261922 - Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists: This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination... Agent: Licata & Tyrrell P.C.

20080261923 - Alkene mimics: Ac-Phe-Tyr-phosphoSer-Ψ[CH═C]-Pro-Arg-NH2AND Fmoc-bis(pivaloylmethoxy)phosphoSer-Ψ[CH═C]-Pro-2-aminoethyl-(3-indole); and their Phospho-(D)-serine stereoisomers are novel compounds. Ψ refers to a pseudo amide. Such novel compounds advantageously may be used as alkene mimics.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080261924 - Method for the treatment of bone disorders: Disclosed are methods for treating bone disorders in mammals. The methods comprise a loading period with a bisphosphonate followed by a maintenance period. The loading dose is two to twenty times per day greater than the corresponding maintenance dose. Also disclosed are compositions and kits for implementing the methods disclosed... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080261925 - Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid: Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D3, 2-methylene-1α,25-dihydroxy-(17E)-17(20)-dehydro-19-nor-vitamin D3, 2-methylene-19-nor-(24R)-1α,25-dihydroxyvitamin D2, 2-methylene-(20R,25S)-19,26-dinor-1α,25-dihydroxyvitamin D3, 2-methylene-19-nor-1α-hydroxy-pregnacalciferol, 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol, (20R)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, 2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalciferol, 2-methylene-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnacalciferol, 2-methylene-(20S)-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnancalciferol,... Agent: Quarles & Brady LLP

20080261926 - Pharmaceutical calcimimetics: This invention relates to novel calcimimetic compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by binding to, and modulating the... Agent: Fish & Richardson P.C.

20080261927 - Stable aqueous suspension: An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.... Agent: Frommer Lawrence & Haug

20080261929 - Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases: The present invention relates to the combination of the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one aromatase inhibitor and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. Aromatase inhibitors which can be combined... Agent: Millen, White, Zelano & Branigan, P.C.

20080261930 - Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application: wherein R is H or C1-C4 alkyl; Z1 is carbonyl or β-hydroxymethylene; X1 is —O— or —S—; R5 is —OH, —OR6, —OCOOR6 or —OCOR7 wherein R6 is C1-C4 alkyl and R7 is C1-C4 alkyl, fluoromethyl or chloromethyl; and the dotted line in ring A indicates that the 1,2-linkage is saturated... Agent: Buchanan, Ingersoll & Rooney PC

20080261928 - Method of treating human preeclampsia employing resibufagenin: A method of treating preeclampsia including administering a therapeutically effective dose of resibufagenin to a patient having preeclampsia. Effecting the determination of the presence of preeclampsia may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does... Agent: Eckert Seamans Cherin & Mellott

20080261933 - Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases: The present invention relates to the combination of the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one lutein-hormone-releasing hormone agonist or antagonist and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. Lutein-hormone-releasing hormone agonists... Agent: Millen, White, Zelano & Branigan, P.C.

20080261934 - Dosage form for hormonal contraception: A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain... Agent: Crowell & Moring LLP Intellectual Property Group

20080261931 - Method and means of preventing and treating sleep disordered breathing: A method of treating or preventing snoring, obstructive sleep apnea (OSA) and/or central sleep apnea (CSA) comprises administering a pharmacologically effective amount a salt of acetylhomotaurine (AcHT) such as calcium acamprosate (CA) to a patient. Also disclosed is the use of AcHT and CA for the manufacture of a medicament... Agent: Dickstein Shapiro LLP

20080261932 - Methods and compositions for the prevention and/or treatment of an exacerbation of asthma: m

20080261935 - 2\" oxo-voruscharin and derivatives thereof: Compounds and pharmaceutical compositions which include 2″ oxo-voruscharin and derivatives are disclosed. The compounds and pharmaceutical compositions are useful in methods of treating cancer, particularly pancreatic cancer.... Agent: Knobbe Martens Olson & Bear LLP

20080261936 - Methods of reducing the body weight of a subject by administering a fatty acid ester of an estrogen or estrogen derivative in an oil and compositions containing the same: Compositions and methods for reducing the body weight of a subject are disclosed. The invention is directed to methods for reducing the body weight in a subject comprising administering therapeutically effective amounts of a fatty acid ester of an estrogen or estrogen derivative in an oil. Furthermore the invention is... Agent: Jones Day

20080261937 - Pharmaceutical compositions and method for treating pediatric hypogonadism: The present invention relates to compositions for treating prepubertal males of adolescent age with insufficient testosterone production using a hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of treating said adolescent males.... Agent: Mayer Brown LLP

20080261938 - Tetracyclic indole derivatives as antiviral agents: The present invention relates to tetracyclic indole compounds of formula (I); wherein R1, R2, R14, R15, A, Ar, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.... Agent: Merck And Co., Inc

20080261939 - Stannsoporfin compositions and administration: Pharmaceutical compositions including stannsoporfin, drug products incorporating pharmaceutical compositions, methods of making pharmaceutical compositions, and methods of treating hyperbilirubinemia with drug products and compositions are disclosed.... Agent: Morrison & Foerster LLP

20080261942 - Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080261941 - Biaryl ether urea compounds: e

20080261940 - N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides: The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R1-R5 are described in the description, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.... Agent: Pharmacia & Upjohn

20080261945 - Compounds having activity at nk3 receptor and uses thereof in medicine: wherein R1 is phenyl optionally substituted by 1, 2 or 3 halogen atoms which halogen atoms may be the same or different; R2 is C1-6alkyl, C3-6cycloalkyl or acetyl; X is oxygen or sulphur; a is 1, 2 or 3; b is 0 or 1; c is 0, 1 or 2;... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080261947 - Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient: Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal... Agent: Sughrue Mion, PLLC

20080261944 - Indole derivatives as antiviral agents: The present invention relates to indole compounds of the formula (I): wherein R1, R2, R3, R4, A, E and X are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections.... Agent: Merck And Co., Inc

20080261946 - Pyrimidine compounds for the treatment of inflammatory disorders: The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds.... Agent: Nixon Peabody, LLP

20080261943 - Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use: or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of... Agent: Cooper & Dunham, LLP

20080261948 - Ligands for g-protein coupled receptors: The invention also provides methods of preparing the compounds, pharmaceutical compositions comprising the compounds and use of the compounds for the preparation of medicaments intended to modulate the activity of one or more members of the G-protein coupled receptor (GPCR) class. Compounds of the invention may be used to create... Agent: Schwegman, Lundberg & Woessner, P.A.

20080261949 - Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same: in which R represents a hydrogen or halogen atom, an —S(O)z(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —SO2NH(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl group or an —NHSO2phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C1-C4)alkyl group or with a (C1-C4)alkoxy group; R1 represents a hydrogen atom or a... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080261950 - Compounds that inhibit cholinesterase: Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The compounds of the invention are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080261951 - Condensed azepines as vasopressin agonists: This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the... Agent: Foley And Lardner LLP Suite 500

20080261952 - Aryl urea derivatives for treating obesity: A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.... Agent: Osi Pharmaceuticals, Inc.

20080261954 - Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment: The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally... Agent: Knobbe Martens Olson & Bear LLP

20080261953 - Compounds, compositions and methods of inhibiting alpha-synuclein toxicity: Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are a symptom or cause of the disease. In one embodiment, the compounds for use in the compositions and methods are heteroaryl acylguanidines, heteroarylhydrazones,... Agent: Fish & Richardson P.C.

20080261955 - Use of pharmaceutical compositions of lofepramine for the treatment of adhd, cfs, fm and depression: In accordance with the present invention, it has been discovered that compounds exhibiting activity as a potent noradrenaline reuptake inhibitor (e.g., a NA:5HT ratio of greater than or equal to about 1000:1), and activity at the dopamine D2 receptor sites (e.g., lofepramine) are effective in the treatment and prevention of... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20080261956 - Substituted phenols as active agents inhibiting vegf production: The present invention relates to methods, compounds, and compositions for inhibiting angiogenesis. More particularly, the present invention relates to methods, compounds, and compositions for inhibiting VEGF production.... Agent: Hoffmann & Baron, LLP

20080261957 - Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives: e

20080261958 - Combination of organic compounds: The present invention relates to a combination comprising: (a) an angiotensin II receptor blocker (ARB), or a pharmaceutically acceptable salt thereof; (b) a calcium channel blocker (CCB), or a pharmaceutically acceptable salt thereof; and (c) one of the two active agents selected from (i) a rennin inhibitor, or a pharmaceutically... Agent: Novartis Corporate Intellectual Property

20080261959 - Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-y)-n-pentanoyl-n[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine: This invention relates to novel crystalline forms of valsartan, namely Form A, Form B, Form C, Form D and their solvates thereof. Processes for the preparation of the novel forms are also provided. The present invention further relates to novel processes for preparing a stable amorphous form of valsartan, and... Agent: Blank Rome LLP

20080261960 - Biologically active methylene blue derivatives: The compounds are biologically active photosensitisers which are strongly photocytotoxic and have application in the areas of photodynamic therapy (PDT), as well as for the diagnosis and detection of medical conditions and related uses in photochemical internalisation, in the production of cancer vaccines, in the treatment and prevention of microbial... Agent: Nixon & Vanderhye, PC

20080261961 - Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases: Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma,... Agent: Hovey Williams LLP

20080261962 - Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators: The invention is directed to a method for alleviating respiratory depression in a subject as a result of disease of pharmacological agents such as opiates, opioids or barbiturates. The invention also discloses pharmaceutical compositions for use with the method, the composition containing in combination, an analgesic, anaesthetic, or a sedative... Agent: Townsend And Townsend And Crew, LLP

20080261963 - Substituted quinobenzoxazine analogs: e

20080261964 - Substituted quinolones ii: The invention relates to substituted quinolones of formula (I) and to methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, in particular against cytomegaloviruses.... Agent: Morrison & Foerster LLP

20080261965 - Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases: Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma,... Agent: Hovey Williams LLP

20080261966 - Bis-aryl sulfonamides: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.... Agent: Brinks Hofer Gilson & Lione

20080261967 - Modulators of central nervous system neurotransmitters: Disclosed are agents having pharmacological activity against cellular receptors and intracellular signaling, particularly receptors and signaling pathways of central nervous system (CNS) neurotransmitters. Also disclosed are related methods and compositions for the treatment or prevention of diseases or disorders using the agents.... Agent: Jones Day

20080261969 - 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them: s

20080261968 - Heterobicyclic metalloprotease inhibitors: The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and... Agent: Amgen Inc.

20080261970 - Sufonamides and uses thereof: Compounds of formula (I), including methods of making and methods of using are described in formula (I).... Agent: Fish & Richardson PC

20080261971 - Novel heterocyclic nf-kb inhibitors: The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, (I) wherein R1 is independently hydrogen, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl or substituted arylalkyl; R2 is independently —NR3R4, (II) or (III) R3 is independently alkyl,... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080261972 - Cgrp receptor antagonists: Compounds of Formula (I), (where variables R1, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also... Agent: Merck And Co., Inc

20080261973 - Sulphonamidoaniline derivatives being janus kinase inhibitors: wherein A is N or CH, W, X, Y and Z are N or CH under the proviso that at least one of the three symbols W, X and Y represent CH, R1 represents NR4R5 or OR4, wherein R4 represents optionally substituted alkyl, optionally substituted cycloalkyl optionally comprising one or... Agent: Novartis Institutes For Biomedical Research, Inc.

20080261974 - Novel chemical compounds: This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080261975 - Tec kinase inhibitors: wherein Q, R1, R2, R3, R4 and R5 are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080261976 - Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same: as well as their salts with inorganic or organic acids, their solvates and/or their hydrates, which exhibit a very high affinity both for the human NK2 receptors for neurokinin A and for the human NK3 receptors for neurokinin B and are antagonists of the said receptors. The invention also relates... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080261978 - Chemokine receptor modulators:

20080261977 - Pyrimidine derivatives as cannabinoid receptor modulators: The present invention relates to novel pyrimidine derivatives such as compounds of the formula (I) and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080261979 - Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals: e

20080261980 - Use of thiazolidinone derivatives as antiangiogenic agents: The invention relates to the use of compounds of general formula (I), in which R1, R2 and X are as defined in the description for the preparation of pharmaceutical compositions for the treatment of pathologies in which inhibition of the interaction between HIF-1α and p300 is beneficial, in particular as... Agent: Seed Intellectual Property Law Group PLLC

20080261981 - Novel derivatives of amino acids for treatment of obesity and related disorders: Novel amino acid derivatives are provided that are useful for management of disorders such as obesity and immunological diseases. The derivatives are also useful in lowering blood glucose levels in hyperglycemic disorders and for treating related disorders such as body weight gain, elevated free fatty acid, cholesterol and triglyceride levels... Agent: Beyer Weaver LLP

20080261982 - Stilbene derivatives as new cancer therapeutic agents: Stilbene derivatives exhibit killing and suppression of growth activity against a variety of cancer cells, and are effective at suppressing tumor growth in vivo. The stilbene derivatives may be used in the treatment of diseases characterized by cell hyperproliferation including human malignancies and non-malignant diseases such as liver cirrhosis. Stilbenes... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080261983 - Substituted morpholinyl compounds: This disclosure relates to novel substituted morpholinyl compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a 5HT4... Agent: Fish & Richardson P.C.

20080261984 - Use of s,s-reboxetine in the treatment of pain: Use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pain condition selected from neuropathic pain, nociceptive pain, cancer pain, back pain, inflammatory pain, musculo-skeletal disorders, visceral pain, pain from strains/sprains, post-operative pain, posttraumatic pain, burns, renal... Agent: Pharmacia Corporation Global Patent Department

20080261986 - Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug: Pharmaceutical formulations suitable for iontophoresis thereof that provide enhanced iontophoretic delivery of an anti-fungal drug to at least one body surface are described. Also described are pharmaceutical formulations suitable for iontophoresis comprising terbinafine and methods for administering terbinafine to a body surface via iontophoresis. In one embodiment, the body surface... Agent: Elmore Patent Law Group, PC

20080261985 - Synthesis and biological activities of new tricyclic-bis-enones (tbes): This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-γ,... Agent: Fulbright & Jaworski L.L.P.

20080261987 - Substituted piperazines: Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated... Agent: Townsend And Townsend And Crew, LLP

20080261988 - Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors: m

20080261989 - Quinoxaline inhibitors of the hedgehog signalling: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I wherein A is a carbocycle or heterocycle; X is alkylene, NR4C(O), NR4C(S), NR4C(NH), NR4SO, NR4SO2, NR4C(O)NH, NR4C(S)NH, C(O)NR4, C(S)NR4, C(NH)NR4, NR4PO or NR4PO(OH) wherein... Agent: Millen, White, Zelano & Branigan, P.C.

20080261990 - Novel pyrimidine derivatives and their use: The present invention relates to novel pyrimidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular diseases, in particular dyslipidemias, arteriosclerosis,... Agent: Barbara A. Shimei Director, Patents & Licensing

20080261991 - Reducing side effects of tramadol: The invention provides methods of reducing the side effects of tramadol. Accordingly, in one embodiment, the invention provides a method of reducing the incidence of newly-discovered side effects related to sexual function in human males taking a tramadol material. The method comprises administering a phosphodiesterase inhibitor to a male taking... Agent: Sheridan Ross PC

20080261992 - Pyridin-2-one compounds and their use as modulators of the dopamine d3 receptor: e

20080261994 - Cyclopropane compounds and pharmaceutical use thereof: wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080261993 - Insecticidal 3-(dihaloalkenyl) phenyl derivatives: Certain novel 3-(dihaloalkenyl)phenyl derivatives have unexpected insecticidal activity. These compounds are represented by formula (I), where R through R5, a, b, D, E, G and U are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula (I), and optionally, an effective... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080261995 - Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor: This invention relates to the combined use of a PDE5 inhibitor and a 5-alpha reductase antagonist in the treatment of lower urinary tract symptoms (LUTS), such as urgency, frequency, nocturia and urge incontinence.... Agent: Pfizer Inc.

20080261996 - Substituted propiolic acid amides and their use for producing drugs: The present invention relates to substituted propiolic acid amides, methods for the production thereof, medicaments containing these compounds and the use thereof for producing medicaments.... Agent: Norris, Mclaughlin & Marcus, Pa

20080261997 - Use of aminoindazole derivatives for the inhibition of tau phosphorylation: R5, R6 and R7 are, independently of one another, chosen from the following radicals: halogen, CN, NO2, NH2, OH, OR8, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, —O—SO2R8, —SO2—O—R8, trifluoromethyl, trifluoromethoxy, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080261998 - Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080261999 - Azabicycloalkane derivatives useful as nicotinic acetylcholine receptor agonists: Compounds of the formula I or a pharmaceutically acceptable salt thereof: processes for their preparation, pharmaceutical compositions which contain them and their uses in therapy.... Agent: Eli Lilly & Company

20080262000 - 5-alkoxyalkyl-6-alkyl-7-aminoazolopyrimidines, process for their preparation, their use for controlling harmful fungi, and compositions comprising them: m

20080262001 - Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection: The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A2A adenosine receptors (ARs).... Agent: Williams Mullen

20080262003 - Methods for treating neoplasia with combination of chemotherapeutic agents and radiation: e

20080262002 - Use of s-adenosylmethionine, vitamin e, and vitamin c for the treatment of oxidative liver injury or insulin resistance: The present invention provides antioxidant compositions comprising S-adenosylmethionine (SAMe), vitamin E and vitamin C and uses thereof for the treatment of liver injury and insulin resistance.... Agent: Merchant & Gould PC

20080262004 - Tgf-beta inhibitors: The present invention is directed to inhibitors of TGF-β of Formula I:... Agent: Eli Lilly & Company

20080262006 - Selective endothelin type-a antagonists: This invention relates to novel endothelin receptor antagonists that selectively inhibit the interaction between Endothelin-1 (ET-1) and endothelin type-A receptors, their derivatives, acceptable acid addition salts. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080262005 - Uracil-type gonadotropin-releasing hormone receptor antagonists and methods related thereto: Compounds having utility as GnRH receptor antagonists and for treatment of a variety of sex-hormone related conditions in both men and women. Such compounds have the following structure (I): (I) wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6, R7, n and X are as defined herein, including stereoisomers,... Agent: Seed Intellectual Property Law Group PLLC

20080262008 - Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as succinate salts: in the form of pharmaceutically acceptable salts and polymorphs thereof. The present invention is directed to methods for preparing and manufacturing crystalline polymorphs or forms of specific anilino-pyrimidine benzenesulfonamide compounds. Methods for converting one crystalline form or polymorph of compounds of formula I as their pharmaceutically acceptable salt polymorph to... Agent: Wyeth Patent Law Group

20080262009 - Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as acetate salts:

20080262010 - Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as d-glucoronate salts:

20080262007 - Hiv inhibiting 5-substituted pyrimidines:

20080262011 - Modulator: The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof. Formula (I), wherein R1 and R2 are each independently H or alkyl; Y is an alkyl group. CONR3R4, COOR5SO2NR16R17, NHSO2R18 or CN; X is an aryl or heteroaryl group, each of which may be... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080262012 - Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximin: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the... Agent: Biotechnology Law Group C/o Portfolioip

20080262013 - Oxymorphone controlled release formulations: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.... Agent: Mayer Brown LLP

20080262014 - Use of camptothecin derivatives for the treatment of proliferative diseases in a fixed dosing regimen: Topoisomerase I inhibitors are administered for the treatment of proliferative diseases according to a once every three day fixed dosing regimens. Furthermore, the invention provides the use of topoisomerase inhibitors to manufacture a medicament which can be used in a fixed dose treatment regimen.... Agent: Novartis Corporate Intellectual Property

20080262016 - Isoquinoline derivatives and methods of use thereof: The invention provides novel classes of Isoquinoline Derivatives. Pharmaceutical compositions and methods of making and using the compounds, are also described.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080262015 - Aryl imidazoles and their use as anti-cancer agents: Therapeutically effective 2,4,5-trisubstituted imidazole compounds are provided. Also provided are methods -of preparing the compounds and pharmaceutical compositions comprising the compounds alone or in combination with other agents. The present invention further provides for the use of the compounds as anti-cancer agents; wherein: R1 is aryl, substituted aryl, heterocycle, substituted... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080262017 - Sugar-free storage-stable antihistaminic syrups: New and improved storage-stable sugar-free antihistaminic syrups are disclosed.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080262018 - Treating allergic and inflammatory conditions: A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080262020 - 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof: m

20080262019 - Optical isomers of (+) and (-)-trans-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1h-pyrido[4,3-b] indole: The present invention represents novel optical isomers produced according the invention that are optic antipodes to each other having individual biological activity which can be used as active ingredients in pharmaceutical compositions with nootropic and sedative activity for treatment of different individual conditions of patients.... Agent: Morgan & Finnegan, L.L.P.

20080262021 - 1h-imidazoquinoline derivatives as prote in kinase inhibitors: The invention relates to imidazoquinolines of formula (I) for use in the treatment of protein kinase dependent diseases; pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease; novel imidazoquinolines; and a process for the preparation of the novel imidazoquinolines.... Agent: Novartis Corporate Intellectual Property

20080262022 - Method of treating actinic keratosis: A method of treating actinic keratosis including applying topically to an actinic keratosis lesion twice per week for a duration of 8 weeks a formulation comprising 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine.... Agent: Edwards Angell Palmer & Dodge LLP

20080262023 - Aminomethyl azaadamantane derivatives and methods of use thereof: The invention relates to compounds that are substituted aminomethyl azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20080262024 - Rifaximin compositions and method of use: Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.... Agent: Biotechnology Law Group C/o Portfolioip

20080262027 - Novel chemical compounds: This invention relates to newly identified compounds for inhibiting YAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of YAK3 proteins.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080262025 - Processes for the preparation of zolpidem and its hemitartrate: The invention relates to the preparation of a non-hygroscopic polymorphic form of zolpidem hemitartrate, designated as Form I, and pharmaceutical compositions including it. The invention also relates to use of the compositions for treating anxiety, sleep disorders and convulsions. The invention also relates to a process for the preparation of... Agent: Ranbaxy Inc.

20080262026 - Therapeutic agents 684: Certain 4,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one and 4,5-dihydropyrrolo[3,2-c]pyridin-4-one compounds of formula I, processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, methods for their therapeutic use and pharmaceutical compositions containing them are described.... Agent: Morgan Lewis & Bockius LLP

20080262028 - Imidazole derivatives as inhibitors of tafia: or any stereoisomeric form of the compound of the formula I or a mixture of these forms in any ratio or a physiologically acceptable salt of the compound of the formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), and to a process for their preparation and to... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080262029 - Acid and base salt forms of gaboxadol: The present invention is directed to novel acid salt forms and base salt forms of the compound gabaoxadol (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol) and hydrates, solvates and polymorphic forms thereof. The invention is further concerned with pharmaceutical compositions containing the salt forms as an active ingredient, methods for treatment of disorders susceptible to amelioration... Agent: Darby & Darby P.C.

20080262030 - Organic compounds: e

20080262031 - 4-aminoquinoline derivatives as antimalarials: New 4-aminoquinoline derivatives having the general formula (I) wherein R, M, X, Y and T have the meaning described in the specification, as potent antimalarials active also on chloroquine-resistant Plasmodium falciparum malaria strains.... Agent: Schneck & Schneck

20080262032 - Isoxazoline derivative and novel process for its preparation: The present invention relates to an isoxazoline derivative having the cyclic carboxylic acid hemiketal moiety of formula (1) for use as caspase inhibitor, a process for preparing it, and a pharmaceutical composition comprising it.... Agent: Birch Stewart Kolasch & Birch

20080262033 - 4-phenyl-5-oxo-1,4,5,6,7,8- hexahydroquinoline derivatives as medicaments for the treatment of infertility: The present invention- relates to 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives having the general Formula (I) wherein the substituents are defined as in the description, or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives in therapy, more... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20080262034 - Lipoic acid derivatives: Lipoic acid derivatives and pharmaceutical formulations containing lipoic acid derivatives are useful in the treatment and prevention of disease characterized by disease cells that are sensitive to lipoic acid derivatives.... Agent: Fitzpatrick Cella Harper & Scinto

20080262035 - Amide derivatives as inhibitors of histone deacetylase: The present invention relates to carboxylic acid derivatives that are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.... Agent: Merck And Co., Inc

20080262036 - Phenyl-[1,2,4]-oxadiazol-5-one derivatives, pharmaceutical compositions and therapeutic use thereof: wherein the R1-R10 and B, U, V, W, X, Y and Z substituents are defined herein. The claimed invention also comprises the compounds isomers and their physiologically acceptable salts as well as processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080262037 - Piperidine derivatives for the treatment of chemokine mediated disease: The present invention provides a compound of a formula (I) wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.... Agent: Fish & Richardson P.C.

20080262038 - Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof: Compounds of Formula: wherein R1, R2, and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080262039 - Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions: m

20080262040 - Chemical compounds: where R1 and R2 are as defined below. These compounds are useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, in particular in the treatment and prevention of disorders mediated by IKK2 mechanisms including inflammatory and tissue repair disorders. Such disorders include rheumatoid arthritis,... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080262041 - Beta-lactams for treatment of cns disorders: e

20080262042 - Pyrrole compounds: wherein R1 is an optionally substituted cyclic group, R2 is a substituent, R3 is an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a halogen atom, a cyano group or a nitro group, R4 and R5 are each a hydrogen atom,... Agent: Edwards Angell Palmer & Dodge LLP

20080262043 - Solid crystalline form of pantoprazole free acid, salts derived therefrom and process for their preparation: The invention relates, in general, to a new solid crystalline form of pantoprazole free acid (denominated “Form III”), salts derived therefrom (e.g., pantoprazole sodium and pantoprazole sodium sesquihydrate) and methods for producing the same. The invention further includes formulating pantoprazole free acid Form III, salts derived therefrom (e.g., pantoprazole sodium... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20080262045 - Metalloproteinase inhibitors: e

20080262044 - Pesticidal mixtures: The present invention relates to a synergistically effective pesticidal composition which comprises, on the one hand, a bisamide and, on the other hand, known fungicidal active ingredients and which is accordingly very well suited to controlling undesirable animal pests such as insects and acarids and also undesirable phytopathogenic fungi.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080262046 - Amidopropoxyphenyl orexin receptor antagonists: The present invention is directed to amidopropoxyphenyl compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent: Merck And Co., Inc

20080262047 - Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients: e

20080262048 - Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives: Novel trifluoromethanesulfonanilide oxime ether compounds useful for controlling endo and/or ectoparasites in the environment are provided, together with methods of making the same, and methods of using the inventive compounds to treat parasite infestations in vivo or ex vivo.... Agent: Intervet/schering-plough Animal Health Patent Department

20080262049 - Therapeutic agent for hematopoietic tumor: [wherein, n represents an integer of 1 to 3, R1 represents a hydrogen atom, R2 represents lower alkyl, or R1 and R2 are combined together to represent alkylene, R3 represents lower alkyl, R4 represents NHSO2R6 (wherein R6 represents hydroxy or the like) or the like, and R5 represents aryl or... Agent: Greenblum & Bernstein, P.L.C

20080262050 - Organic compounds: are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. The compounds of... Agent: Novartis Corporate Intellectual Property

20080262052 - Methods for the treatment of metabolic and glucose utilization disorders through the administration of oxadiazolones and derivatives thereof as peroxisome proliferator - activated receptor (ppar) delta agonists: in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080262051 - Triazole derivatives which are smo antagonists:

20080262053 - Use of pramipexole for treating moderate to severe restless legs syndrome (rls): The invention relates to the use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole, the (+)- or (−)-enantiomer thereof or the pharmacologically acceptable salts thereof for treating moderate to severe Restless Legs Syndrome (RLS).... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080262054 - Pharmaceutical composition containing thiazolidinedione compound: e

20080262055 - Macrocyclic acyl guanidines as beta-secretase inhibitors: wherein R1, R2, R3, R4, R5, n and X as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the... Agent: Louis J. Wille Bristol-myers Squibb Company

20080262056 - Oxindole oxazolidinones as antibacterial agents: The present invention relates to novel oxazolidinones derivatives of oxindoles of formula I or a pharmaceutically acceptable salt thereof wherein: Y1 is CH or CF; R1 is —C1-4alkyl, optionally substituted with a fluoro atom, or R1 is —C3-5cycloalkyl; and R2 is —C1-2alkyl. These compounds are useful as antibacterial agents.... Agent: Pfizer Inc Steve T. Zelson

20080262057 - Diarylisoxazolines: The invention disclosed in this document is related to field of pesticides and their use in controlling pests.... Agent: Dow Agrosciences LLC

20080262058 - Macrocylic inhibitors of hepatitis c virus: e

20080262059 - Methods of treatment and pharmaceutical composition: selected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency... Agent: Novartis Corporate Intellectual Property

20080262061 - Composition and use of a liquid fungicidal formulation of myclobutanil or tebuconazole fungicide: A fungicide composition containing a fungicide compound and a surfactant, wherein the fungicide is fully dissolved in the surfactant, and wherein the fungicide is selected from either myclobutanil or tebuconazole or a mixture thereof.... Agent: Connolly Bove Lodge & Hutz LLP

20080262060 - Crystalline forms of deferasirox: The present invention provides novel crystalline forms of deferasirox, methods for their production, and methods for conversion of the novel forms to the known crystalline form I.... Agent: Kenyon & Kenyon LLP

20080262062 - Method of treating diseases with parp inhibitors: The present invention discloses various diseases that have up-regulated or down-regulated PARP and can be treated with PARP inhibitors or PARP activators, respectively. The examples of the diseases include cancer, inflammation, metabolic disease, CVS disease, CNS disease, disorder of hematolymphoid system, disorder of endocrine and neuroendocrine, disorder of urinary tract,... Agent: Wilson Sonsini Goodrich & Rosati

20080262063 - Novel inhibitors of glutaminyl cyclase: e

20080262064 - Novel compounds for the treatment of gi disorders 682: The present invention relates to novel imidazole compounds having a positive allosteric GABAB receptor (CUR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux... Agent: Pepper Hamilton LLP

20080262065 - Novel inhibitors of glutaminyl cyclases: e

20080262066 - Azole derivatives as cannabinoid cb1 receptor antagonists: A novel azole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provides a method for preparing same, a pharmaceutical composition containing same,... Agent: Sughrue Mion, PLLC

20080262067 - Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof: A pharmaceutical composition comprising idazoxan or derivatives and their therapeutically acceptable salts, racemates, optically active isomers and polymorphs.... Agent: Birch Stewart Kolasch & Birch

20080262068 - Method of tonic treatment with oxyphenbutazone derivatives: The present invention provides a method of tonic treatment of an aging mammalian subject, or a subject suffering from mild inflammation, lupus, fatigue, lethargy or the aftereffects of infection, disease or treatment, comprising administration of a compound of formula (I) or a salt thereof. Said compounds are also used as... Agent: Bacon & Thomas, PLLC

20080262069 - Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment: The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy) ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080262070 - Pharmaceutically active tetrahydro-pyrrolizinone compounds: Tetrahydro-pyrrolizinone compounds which mediate the activity of LFA-1 with its ligands involved in cell adhesion, migration and activation.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080262071 - Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder: In accordance with the present invention, it has been discovered that pindolol provides a highly effective treatment for PMS and/or PMDD. As such, the present invention generally relates to methods and compositions for treating and/or preventing PMS, or symptoms associated therewith including premenstrual tension or premenstrual dysphoria. The methods and... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20080262072 - Compositions and kits comprising a melatonin component and a flavanol component: Disclosed herein are compositions and kits, wherein each composition comprises a melatonin component, a flavanol component, or both, and wherein each kit comprises a melatonin component and a flavanol component. The compositions and kits are useful for restorative sleep function and enhanced energy. Further disclosed herein are methods of using... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080262073 - pyrrolic derivatives with histone deacetylase inhibitory activity: The invention describes new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases.... Agent: Ostrolenk Faber Gerb & Soffen

20080262074 - Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-(phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid or solvates or hydrates thereof, as well as crystalline salts characterized by their X-ray powder diffraction pattern are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic... Agent: Pfizer Inc.

20080262075 - Pyrrolidine derivatives as muscarinic receptor antagonists: This invention relates to pyrrolidine derivatives, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Processes for the preparation of described compounds, pharmaceutical compositions containing the described compounds and the methods for treating the diseases mediated... Agent: Ranbaxy Inc.

20080262076 - Novel tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain: i

20080262077 - Pharmaceutical formulations containing lipoic acid derivatives: Pharmaceutical formulations containing lipoic acid derivatives are made.... Agent: Fitzpatrick Cella Harper & Scinto

20080262078 - Pharmaceutical compositions: The present invention relates to a process for the preparation of a stable lyophilized form of a water insoluble drug suitable for parenteral use and pharmaceutical compositions comprising such lyophilized form of the drug.... Agent: Pharmaceutical Patent Attorneys, LLC

20080262079 - Cannabinoid compositions and methods of use thereof: The present invention provides cannabinoid compositions and the use of such cannabinoid compositions in the treatment of autoimmune and/or inflammatory diseases and disorders. For example, the present invention provides a method of using tetrahydrocannabinoid (THC) compounds in the treatment of autoimmune and/or inflammatory diseases and disorders.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080262080 - Allergy suppressive agent: Namely, it is intended to provide an allergy suppressive agent comprising chrysin, more specifically speaking, a histamine release inhibitory agent comprising chrysin; a composition comprising chrysin that is a composition for treating a disease or condition relating to the production of IgE; a composition comprising chrysin that is a composition... Agent: Birch Stewart Kolasch & Birch

20080262081 - Novel use of nutraceutical compositions comprising resveratrol: The use of resveratrol, a derivative, metabolite or analogue thereof, in combination with at least one additional component selected from EGCG, coenzyme Q-IO, genistein, lycopene, hydroxytyrosol and polyunsaturated fatty acids in the manufacture of a nutraceutical composition for delaying aging and/or for the treatment or prevention of age-related diseases in... Agent: Nixon & Vanderhye, PC

20080262082 - Composition containing s-(-)-tulipalin b or acetylated-s-(-)-tulipalin b: The present invention provides S-(−)-tulipalin B, acetylated-S-(−)-tulipalin B and an antibacterial composition comprising the same. The active compound tulipalin B and composition of the present invention exhibit superior and stable antibacterial activity over a broad range of temperature and pH, as compared to conventional natural antibacterial agents used in related... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080262083 - Antibacterial agents: D-(threo)-1-aryl-2-disubstitutedacylamido-3-fluoro-1-propanol compounds compounds and analogues thereof (“Fenicol Compounds”), compositions comprising an effective amount of a Fenicol Compound, and methods for treating or preventing a bacterial infection in an animal comprising administering to an animal in need thereof an effective amount of a Fenicol Compound are disclosed.... Agent: Townsend And Townsend And Crew, LLP

20080262084 - Stable emulsion compositions for intravenous administration having preservatie efficacy: Monoglycerides, especially Monolaurin, are used to protect intravenously administrable oil-in-water emulsion compositions against growth of E. coli, P. aeruginosa S. aureus and C. albicans. The compositions can be medicaments containing lipophilic drugs, especially Propofol, and/or total intravenous nutritional compositions.... Agent: Thorpe North & Western, LLP.

20080262085 - Method for restructuring keratin fibers: The invention relates to a method for restructuring keratin fibers during which a keratin fiber is brought into contact with cystine and with at least one dicarboxylic acid having 2 to 10 carbon atoms. The invention also relates to preparations for use in this method.... Agent: Jeffer, Mangels, Butler & Marmaro, LLP

20080262086 - Substituted anthranilic acids: Disclosed herein are substituted anthranilic acids, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of hypertension, edema associated with congestive heart failure, hepatic disease, renal disease including nephrotic syndrome, or clearance of toxic substances from the body.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080262087 - T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds: s

20080262088 - Methods, compounds, and compositions for treating metabolic disorders and diabetes: Disclosed herein are methods, compounds and compositions for preventing or treating a pancreatic disorder, including diabetes mellitus (e.g. type 1 and/or type 2 diabetes). The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to... Agent: Millen, White, Zelano & Branigan PC

20080262089 - Process for the preparation of tamsulosin: The invention includes an improved process for producing tamsulosin comprising reacting 5-(2-aminopropyl)-2-methoxybenzenesulfonamide with 2-(o-ethoxyphenoxy)ethyl bromide in an organic phosphite solvent to obtain tamsulosin. Optically pure (R)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide can be employed to produce optically pure (R)-tamsulosin product. The organic phosphite solvent utilized in the reaction can include tri-alkyl phosphites such as triethyl... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20080262090 - Guanylhydrazone salts, compositions, processes of making, and methods of using: The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their use.... Agent: Law Office Of John K. Pike, PLLC

20080262091 - Infiltration of capsaicin into surgical sites and open wounds: The present invention provides compositions and methods for attenuating or relieving pain at a site in a human or animal in need thereof by infiltrating at a surgical site or open wound in a human or animal a dose of capsaicinoid in an amount effective to denervate the surgical site... Agent: Davidson, Davidson & Kappel, LLC

20080262092 - Regulation of osteopontin: The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080262093 - Methods and compositions for treating obesity: The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject. The present invention also relates to the use of PGC-1 expression levels to determine the safe dosage range for known or putative respiration uncoupling agents for use as anti-obesity therapeutics. The present... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080262095 - Protectant for uv-induced skin damage: The present invention provides a method for protecting against UV radiation-induced skin damage. Specifically, compositions including dapsone are administered to provide UV protection. The dapsone compositions may be administered orally, or by other parenteral routes, such as topically, transdermally, by inhalation, and the like.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080262094 - Treatment of comorbid premature ejaculation and erectile dysfunction: The invention provides a method of treating comorbid premature ejaculation and erectile dysfunction. In particular, the method comprises administering an effective amount of a tramadol material and an effective amount of a phosphodiesterase inhibitor. The invention also provides a pharmaceutical composition comprising a pharmaceutically-acceptable carrier, a tramadol material and a... Agent: Sheridan Ross PC

20080262096 - Squaric acid derivatives: Novel squaric acid compounds of the formula (I), in which R, R1, R1′, R2 and X have the meanings indicated in Claim (1), are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular... Agent: Millen, White, Zelano & Branigan, P.C.

20080262098 - Composition for destroying thread algae: A composition of alkali carbonate peroxyhydrate in a quantity of 45 to 85% by weight relative to a total amount of the composition and an alkali hydrogen carbonate is provided for combating pathogenic germs and parasites in water of aquaculture, ponds, and aquariums; for destroying thread algae in water; for... Agent: Gudrun E. Huckett Draudt

20080262097 - Formulations: An antimicrobial formulation containing (a) a peroxide selected from the group consisting of diacyl peroxides, alkyl hydroperoxides and metal peroxides and (b) a benzoquinone or hydroquinone. The formulation may in particular be used against staphylococci or propionibacteria, more particularly to treat skin and skin structure conditions such as acne.... Agent: Beyer Weaver LLP

20080262099 - Inhibition of tumour cell migration: The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration.... Agent: Wolf Greenfield & Sacks, P.C.

20080262100 - Method of preparing carrier liquids: The invention provides a method for the preparation of a carrier liquid which comprises the steps of: (I) preparing an emulsion comprising: a) an aqueous phase, b) A second liquid phase which is volatile and which is immiscible with aqueous phase (a), c) A carrier material which is soluble in... Agent: Unilever Patent Group

20080262101 - Method to prepare a personal care composition from a base composition and a method to prepare the base composition: A base composition is provided which comprises water and a non-ionic surfactant mixture. The base composition is suitable for use in preparing a personal care product.... Agent: Unilever Patent Group

20080262102 - Hydrophilic/hydrophobic polymer networks based on poly(caprolactone fumarate), poly(ethylene glycol fumarate), and copolymers thereof: Improved methods for preparing polyethylene glycol fumarate) are disclosed. Methods for chemically crosslinking or photocross-linking hydrophilic polyethylene glycol fumarate) with hydrophobic polymers such as poly(propylene fumarate) (PPF) and poly(caprolactone fumarate) (PCLF) to form various hydrogels (FIG. 1) with controllable hydrophilicity are also disclosed. The hydrogels are useful in the fabrication... Agent: Quarles & Brady LLP

20080262104 - Aqueous polyvinyl acetate dispersions having high shearing stability: Processes comprising: providing a monomer composition comprising a vinyl acetate monomer component and second monomer component comprising an additional monomer selected from the group consisting of acrylic acid, methacrylic acid and mixtures thereof in an amount of 0.05 to 5% by weight, wherein the vinyl acetate monomer component and the... Agent: Connolly Bove Lodge & Hutz, LLP

20080262103 - Clear oil-in-water emulsions: This invention relates to clear oil-in-water emulsions with an electrosteric surfactant, their preparation and their use in personal care products.... Agent: Philip S. Johnson Johnson & Johnson

20080262105 - 1-vinylpyrrolidin-2-one/ester copolymers: The present invention refers to segment copolymers comprising segments “A” having polyvinylpyrrolidone (PVP) structure and segments “B” having a polyester 5 structure and the process for their preparation and their use.... Agent: Jay S. Cinamon Abelman, Frayne & Schwab

20080262106 - Direct compressible trehalose solids: The present invention relates to direct compressible crystalline or semi-crystalline trehalose solids having a crystal form selected from the group consisting of trehalose dihydrate and mixtures of trehalose dihydrate and anhydrous trehalose, and having a specific surface area of at least 0.25 m2/g and products or tablets containing these. A... Agent: Fish & Richardson P.C.

20080262107 - Pharmaceutical compositions with enhanced performance: Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.... Agent: Chernoff, Vilhauer, Mcclung & Stenzel

20080262108 - Method: The invention provides methods of screening test compounds for their ability to reduce retention of atherogenic lipoproteins in atherogenesis by measuring their activity as a modulator of the binding affinity of CEL (Carboxyl Ester Lipase) to various receptors. The invention further provides methods for the use of active modulators of... Agent: Fulbright & Jaworski L.L.P.

20080262109 - Method for producing liquid preparations having a solid body content: A method for producing a liquid preparation having a solid body content and the resulting liquid preparation. According to the method, the addition of at least a portion of the solid bodies takes place only (a) in the last stage of the method preceding the pouring of the liquid preparation... Agent: Paul & Paul

20080261861 - 2-micron family plasmid and use thereof: The present invention provides a 2 μm-family plasmid comprising a polynucleotide sequence insertion, deletion and/or substitution between the first base after the last functional codon of at least one of either a REP2 gene or an FLP gene and the last base before the FRT site in an inverted repeat... Agent: Synnestvedt & Lechner, LLP

20080261862 - Materials and methods for modulating signalling by alpha-v integring molecules: It is disclosed that the αvβ5 integrin mediates the proliferative signal provided by CD23 to pre-B cells. The region of CD23 which interacts with αvβ5 has been defined, and found to interact with a site on the integrin distinct from that which binds RGD. The invention provides methods for disrupting... Agent: Dann, Dorfman, Herrell & Skillman

20080261864 - Combination of nateglinide or repaglinide with at least one further antidiabetic compound: The present invention relates to a combination of organic compounds which comprises at least two antidiabetic agents, preferably with different modes of action, in which the active ingredients are in each case present in free form or in the form of a pharmaceutically acceptable salt and, optionally, at least on... Agent: Novartis Corporate Intellectual Property

20080261863 - Pegylation of vasoactive intestinal peptide (vip) / pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use: This invention relates to modified Vasoactive Intestinal Peptide (VIP)/Pituitary Adenylate Cyclase Activating Peptide (PACAP) Receptor 2 (VPAC2) agonists (VPAC2 agonists) comprising a VPAC2 agonist linked to a polyethylene glycol polymer, as well as related formulations, dosages, and methods of administration thereof for therapeutic purposes. These VPAC2 agonists, compositions, and methods... Agent: Barbara A. Shimei Director, Patents & Licensing

20080261869 - Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity: Embodiments herein illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating a bacterial infection, or a viral infection in a subject. More particularly, embodiments herein relate to compounds including naturally occurring and synthetic compositions having alpha-1 antitrypsin activity but... Agent: Faegre & Benson LLP Patent Docketing

20080261866 - Compositions comprising glycosaminoglycan and nonsteroidal anti-inflammatory drug: Pharmaceutical compositions comprising of glycosaminoglycan or salts thereof, preferably chondroitin or salts thereof, more preferably chondroitin sulphate, and nonsteroidal anti-inflammatory drug(s) or salts thereof, optionally with pharmaceutically acceptable excipient(s) are described. The compositions of the present invention provide gastrosparing effect in conditions where nonsteroidal anti-inflammatory drug(s) or their salts are... Agent: Ladas & Parry LLP

20080261868 - Methods and compositions for treating diabetes: The instant invention provides a method of treating an animal suffering a disease characterized by excessive apoptosis by administering a therapeutically effective amount of at least one serine protease inhibitor and thereafter monitoring a decrease in apoptosis. The inhibitor of the invention includes α1-antitrypsin or an α1-antitrypsin-like agent, including, but... Agent: Don D. Cha

20080261865 - Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20080261867 - Soluble inhibitors of vascular endothelial growth factor and use thereof: The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with... Agent: David S. Resnick

20080261877 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080261888 - Antibodies to pdgf-d: PDGF-D, a new member of the PDGF/VEGF family of growth factors, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications, including methods... Agent: Fulbright & Jaworski, LLP

20080261873 - Growth-hormone secretagogues: Disclosed are methods of treating a disorder of the stomach, intestine or duodenum in a human subject. The method includes administering to the subject, a pharmaceutical composition comprising a compound that increases gastrointestinal motility (e.g., by modulating myenteric nerve activity) and/or induces the secretion or production of growth hormone.... Agent: Fish & Richardson PC

20080261884 - Lung volume reduction therapy using crosslinked biopolymers: One aspect of the present invention relates to bronchoscopic lung volume reduction using solutions of biopolymers that can be polymerized in situ with a crosslinker and a polymeric additive which accelerates the cross-linking reaction. In certain embodiments, the biopolymer solutions can be in the form of a foam or gel.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080261879 - Method of inducing and maintaining neuronal cells: The present invention makes available a method for inducing neuronal differentiation and preventing the death or degeneration of neuronal cells both in vitro and in vivo. The subject method stems from the unexpected finding that, contrary to traditional understanding of neural induction, the default fate of ectodermal tissue is neuronal... Agent: Ropes & Gray LLP

20080261889 - Method for determining the risk of developing a neurological disease: Methods and kits are provided for determining whether a subject is at risk of developing a neurological disease such as Alzheimer's disease and multiple sclerosis. The methods and kits are based on the detection of one or more nucleic acid variants in the MBL gene of the subject.... Agent: Howrey LLP-hn

20080261876 - Method for purifying marine collagen and the processing thereof into porous sponges: Methods are provided for purifying marine collagen and for processing the collagen into porous sponges. Products produced with these methods and the use of the products are also provided.... Agent: Panitch Schwarze Belisario & Nadel LLP

20080261875 - Method for treating cardiovascular disease: A method for treating cardiovascular disease comprising administering an effective amount of FGF-21 or an FGF-21 compound to a patient in need thereof.... Agent: Eli Lilly & Company

20080261878 - Method of inducing the formation of neurofibrillary tangles in transgenic animals: The present invention discloses a method and an in-vivo assay system useful for the identification and testing of modulating agents as well as for the validation of therapies of neurodegenerative diseases associated with the formation of neurofibrillary tangles, in particular Alzheimer's disease. The present invention is based on the surprising-finding... Agent: Jacobson Holman PLLC

20080261882 - Methods for inhibiting heregulin and treating cancer: The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to... Agent: Cohen & Grigsby, P.C.

20080261874 - Mutants of trichosanthin with anti-tumor activity and lowered side-effects: The invention provides the mutants and coding genes of trichosanthin (TCS). The mutants thereof are the TCS mutants with the single or double alternation of tyrosine-55 and aspartate-78 (counted from N-terminus), wherein the tyrosine-55 is mutated to an aliphatic amino acid and aspartate-78 is mutated to an amino acid with... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20080261885 - Process for the extraction, purification and enzymatic modification of soy 7s globulin alpha' subunit for use as hypocholesterolemizing agent: A process for the extraction, purification and enzymatic modification of β-conglycinin α′ subunit, wherein β-conglycinin is selectively extracted from ground, defatted soy, then precipitated by treatment with aqueous ethanol; the enriched fraction is then subjected to Metal Affinity Chromatography (MAC) in denaturant conditions to obtain the α′ subunit, which is... Agent: Young & Thompson

20080261883 - Runx3 gene showing anti-tumor activity and use thereof: The present invention relates to a RUNX3 gene showing anti-tumor activity which is essentially involved in TGF-β-dependent programmed cell death (apoptosis) and use thereof. In addition, the present invention finds that RUNX3 gene expression is suppressed in the various gastric cancer and lung cancer cell lines. The suppression of the... Agent: Lucas & Mercanti, LLP

20080261886 - Single-dose administration of factor viia: The present invention provides methods for preventing and/or treating bleeding episodes by administering a single dose of a Factor VIIa equivalent. Preferably, the single dose comprises between about 150 and about 500 ug/kg Factor VIIa equivalent.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080261880 - Synthetic approach to designed chemical structures: This invention relates to the chemical design and production of peptides, peptide structure and three dimensional conformation was assessed using NMR, circular dichroisin and pulsed field gradient NMR. In addition, this invention relates to peptides produced by these methods and to methods for using the peptides.... Agent: Mueting, Raasch & Gebhardt, P.A.

20080261887 - Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080261872 - Use of ghrelin and unacylated ghrelin compositions in insulin-related disease conditions: A novel combination of ghrelin and unacylated ghrelin is described herein. Methods of administering and uses of this combination to alter an insulin-associated parameter are also described. Compositions and packages containing ghrelin and/or one of its analogs and nonacylated ghrelin and/or one of its analogs as well as the uses... Agent: Wilmerhale/boston

20080261881 - Use of human chorionic gonadotropin (hcg) orally or for injection for the treatment of mood disorders and alcoholism: n

20080261890 - Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions: The invention further features novel methods and compositions for treating and preventing dry eye by administration of neurotransmitters and/or neuropeptides, optionally in formulation with various other agents, as well as kits for the use of such novel formulations and methods.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080261870 - Use of the pro-peptide domain of lysyl oxidase as a therapeutic agent: A therapeutic composition that includes an active portion of the lysyl oxidase pro-peptide in a pharmaceutically acceptable carrier substance and methods of using such a therapeutic composition are disclosed. The active agent does not have lysyl oxidase enzymatic activity. Preferably, the active polypeptide is active in inhibiting cell growth in... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20080261871 - Y2/y4 selective receptor agonists for therapeutic interventions: Y receptor agonists which are selective for Y2 and Y4 receptors over the Y1 receptor are useful for treatment of, for example obesity, are (a) PP-fold peptides or PP-fold peptides mimics which have (i) a C-terminal Y receptor-recognition amino acid sequence represented by —X-Thr-Arg-X3-Arg-Tyr-C(=0)NR1R2 wherein R1 and R1 are independently... Agent: Banner & Witcoff, Ltd.

20080261891 - Compositions and methods for using syringopeptin 25a and rhamnolipids: The present invention provides a therapeutic composition having at least one syringopeptin and at least one rhamnolipid so that the composition has one or more of the following activities: antibacterial; antifungal; and antitumor activity. The therapeutic composition includes the following: a therapeutically effective amount of a syringopeptin; a therapeutically effective... Agent: Utah State University/workman Nydegger

20080261892 - Acid addition salts of ac-phscn-nh2: Acid addition salts of Ac—PHSCN—NH2, methods of making acid addition salts of Ac—PHSCN—NH2, pharmaceutical compositions of acid addition salts of Ac—PHSCN—NH2, methods of using acid addition salts of Ac—PHSCN—NH2 and pharmaceutical compositions thereof to treat diseases associated with angiogenesis and aberrant vascularization and methods of preventing degradation of Ac—PHSCN—NH2 by... Agent: Jones Day

20080261893 - Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing: A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg alternatively about 0.0001 to about 3... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-1118

20080261894 - Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis: The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of rasagiline or the pharmaceutically acceptable salt thereof, wherein the amounts when taken together are effective to alleviate a... Agent: Cooper & Dunham, LLP

20080261898 - Composition and method for cancer treatment and prevention: Compounds, compositions, methods and kits are provided for treating, reducing the risk of, or preventing diseases and/or conditions, such as diseases associated with angiogenesis and/or abnormal cell proliferation, such as cancer. Compounds of the present invention have antiangiogenic and anti-cancer activity with minimum toxic effects on normal cells. Methods for... Agent: Wilson Sonsini Goodrich & Rosati

20080261897 - Formulation containing a polyphenol-containing composition and isomaltulose: The present invention relates to formulations containing isomaltulose and a polyphenol-containing composition, uses of same and the use of isomaltulose for masking unwanted taste components, in particular bitter substances, in formulations, in particular in formulations containing tea extracts.... Agent: Ostrolenk Faber Gerb & Soffen

20080261895 - Isolated hydroxy and n-oxide metabolites and derivatives of o-desmethylvenlafaxine and methods of treatment: The present invention provides novel isolated compounds characterized as metabolites or derivatives of desmethylvenlafaxine including hydroxy-DV metabolites, hydroxy-DV-glucuronide metabolites, N-oxide-DV metabolites, and benzyl-hydroxy-DV metabolites. The invention includes pharmaceutical compositions comprising any of the metabolites or derivatives of the invention in combination with a pharmaceutically acceptable carrier or excipient. The invention... Agent: Wyeth/finnegan Henderson, LLP

20080261896 - Testosterone generating and metabolizing enhancer: A testosterone generating and metabolizing enhancer is proposed in the invention, which increases concentrations of testosterone in both seminal vesicle and bloodstream, and may further promote the gene expression of metabolizing testosterone into 5α-reductase of dihydrotestosterone. The testosterone generating and metabolizing enhancer of the invention is characterized in that an... Agent: Bacon & Thomas, PLLC

20080261899 - Agent for controlling bcl-2 expression comprising ginsenoside f1 as an active component: The present invention relates to an agent for controlling Bcl-2 expression comprising ginsenoside F1 (20-O-β-D-glucopyranosyl-20(S)-protopanaxatriol) represented by the following formula 1 as an active component.... Agent: Sughrue Mion, PLLC

20080261900 - Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria: Compositions comprise a fluoroquinolone having Formulae I-VIII for treating, reducing, ameliorating, or preventing infections caused by some bacteria that are resistant to an antibacterial drug. Methods for treating, reducing, ameliorating, or preventing such infections use such compositions.... Agent: Bausch & Lomb Incorporated

20080261901 - Cosmetic composition comprising beta-fructosyl-l-ascorbic acid for skin whitening: The present invention is related to novel cosmetic composition comprising β-fructosyl-L-ascorbic acid derivatives produced by fructose conversion reaction using by ascorbic acid and the compounds shows potent inhibiting effect on the activity of tyrosinase enzyme, therefore, it can be useful as a skin whitening cosmetic composition as an cream, skin,... Agent: Kirk Hahn

20080261902 - Pharmaceutical composition containing polydatin and its application: A composition includes polydatin and solvent for dissolving the polydatin, wherein the solvent comprises alcohol in a range between 40 and 95% by volume, propanediol in a range between 0 and 60% by volume, and water in remaining volume. The concentration of the polydatin must be at least 6 mg/ml.... Agent: David And Raymond Patent Firm

20080261912 - Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same: Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.... Agent: Marina Larson & Associates, LLC

20080261904 - Chimeric gapped oligomeric compounds: The present invention provides double stranded compositions wherein the first strand comprises three different regions and the second strand is native RNA. Each region has native or modified ribofuranosyl sugar moieties that are different than those of the other two regions. At least a portion of the first oligomeric compound... Agent: Woodcock Washburn LLP

20080261907 - Compositions and methods of sphingosine kinase inhibitors in radiation therapy of various cancers: The present invention relates to Sphingosine kinase inhibitors that are useful for treating various cancers. The invention further relates to compositions and methods of SPK inhibitors, including siRNAs, which specifically block gene expression of SPK and potentiates the effect of radiation in the treatment of various cancers.... Agent: Hogan & Hartson L.L.P.

20080261910 - Diagnostic methods based on polymorphisms of glucosyltransferase-like protein: The present invention arises from the identification of an association between the gene encoding glucosyltransferase-like protein (GT) and osteoarthritis (OA). It therefore relates to diagnostic techniques for determining a patient's susceptibility to develop OA by detecting all or part of the GT gene, its precursors or products (mRNA, cDNA, genomic... Agent: Fish & Richardson P.C.

20080261909 - Gene delivery to organs: Application of a virus with poloxamer alone onto atria results in diffuse epicardial gene transfer with negligible penetration into the myocardium. Progressive increases in protease concentration, however, allow transmural gene transfer. After protease exposure, echocardiographic left atrial diameter does not change. Left atrial ejection fraction decreases on post-operative day 3,... Agent: Banner & Witcoff, Ltd.

20080261906 - Methods and compositions for identifying anti-hcv agents: The invention features methods and compositions for screening for agents that modulate replication of a virus, particularly Flaviviridae virus (particularly hepatitis C virus (HCV)), where the methods provide for detection of agents that modulate the binding of TBC and NS5A, the inhibition of TBC activity, inhibition of Rab1 activity, and/or... Agent: Bozicevic, Field & Francis LLP

20080261908 - Microrna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer: The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of breast cancer. The invention also provides methods of identifying anti-breast cancer agents.... Agent: Macmillan Sobanski & Todd, LLC

20080261905 - Modified nucleosides for rna interference: The present invention relates to the use of modified nucleotides and single or double stranded oligonucleotides having at least one of said modified nucleotides for performing RNA interference. The modified nucleotides are selected from 6-membered ring containing nucleotides such as hexitol, altritol, O-substituted or O-alkylated altritol, cyclohexenyl, ribo-cyclohexenyl and O-substituted... Agent: Knobbe Martens Olson & Bear LLP

20080261903 - Regulation of kinase, regulated in copd kinase (rc kinase): Reagents which regulate human RC Kinase activity and reagents which bind to human RC Kinase gene products can be used to regulate this protein for therapeutic effects. Such regulation is particularly useful for treating chronic obstructive pulmonary disease, asthma, cancer, and diseases in which cell signaling is defective.... Agent: Jones Day

20080261911 - Uses of diphenyl/diphenylamine carboxylic acids: The present invention demonstrates that chemical-induced degradation of Sp proteins by a specific sub-class of non-steroidal anti-inflammatory drugs inhibited cancer cell growth, angiogenesis and metastasis of cancer cells. The inhibitory effects of these compounds were demonstrated in vitro and in vivo. Hence, the results discussed herein indicate that these compounds... Agent: Benjamin Aaron Adler Adler & Associates

20080261913 - Compounds and pharmaceutical compositions for the treatment of liver disorders: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including liver cancer and metabolic diseases, such as diabetes, hyperlipidemia, atherosclerosis, and obesity. Specifically, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-cancer agents.... Agent: Jones Day

20080261914 - Stabilization of vitamin b12: The invention relates to preparations comprising vitamin B12 and a butanol, and to the use of butanol for stabilizing vitamins.... Agent: Bayer Healthcare LLC

20080261915 - Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate: This invention relates to wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate.... Agent: Steinfl & Bruno

20080261916 - Synergistic prebiotic compositions: The invention relates to synergistic compositions comprising prebiotic components selected from fructose polymers GFn and Fm, either containing a glucose (G) end-group, or without a glucose end-group, and one or more component of a group of prebiotics consisting of modified or unmodified starch and partial hydrolysates thereof, partially hydrolysed inulin,... Agent: Hahn & Voight PLLC

20080261920 - 2-aminooxazolines as taar1 ligands: X, Y, R1, R2, and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080261919 - Camptothecin-analog with a novel, \"flipped\" lactone-stable, e-ring and methods for making and using same: The present invention discloses: (i) a novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (iii) pharmaceutically-acceptable formulations comprising said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one... Agent: Scott A. Whitaker, Ph.d., J.d. - Sr. Intellectual Property Counsel

20080261917 - Isoindolin-1-one derivatives: or a prodrug and/or a pharmaceutically acceptable salt thereof, wherein X is O, N or S; R1 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; R2 is hydrogen,... Agent: Notaro And Michalos

20080261918 - Silicon compounds and their use: A compound of any of formulas (I) to (V): wherein at least one of Y and Z includes a Si atom, is of utility in therapy.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080261921 - Fused ring heterocycle kinase modulators: The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.... Agent: Wilson Sonsini Goodrich & Rosati

20080261922 - Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists: This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination... Agent: Licata & Tyrrell P.C.

20080261923 - Alkene mimics: Ac-Phe-Tyr-phosphoSer-Ψ[CH═C]-Pro-Arg-NH2AND Fmoc-bis(pivaloylmethoxy)phosphoSer-Ψ[CH═C]-Pro-2-aminoethyl-(3-indole); and their Phospho-(D)-serine stereoisomers are novel compounds. Ψ refers to a pseudo amide. Such novel compounds advantageously may be used as alkene mimics.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080261924 - Method for the treatment of bone disorders: Disclosed are methods for treating bone disorders in mammals. The methods comprise a loading period with a bisphosphonate followed by a maintenance period. The loading dose is two to twenty times per day greater than the corresponding maintenance dose. Also disclosed are compositions and kits for implementing the methods disclosed... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080261925 - Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid: Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D3, 2-methylene-1α,25-dihydroxy-(17E)-17(20)-dehydro-19-nor-vitamin D3, 2-methylene-19-nor-(24R)-1α,25-dihydroxyvitamin D2, 2-methylene-(20R,25S)-19,26-dinor-1α,25-dihydroxyvitamin D3, 2-methylene-19-nor-1α-hydroxy-pregnacalciferol, 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol, (20R)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, 2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalciferol, 2-methylene-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnacalciferol, 2-methylene-(20S)-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnancalciferol,... Agent: Quarles & Brady LLP

20080261926 - Pharmaceutical calcimimetics: This invention relates to novel calcimimetic compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by binding to, and modulating the... Agent: Fish & Richardson P.C.

20080261927 - Stable aqueous suspension: An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.... Agent: Frommer Lawrence & Haug

20080261929 - Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases: The present invention relates to the combination of the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one aromatase inhibitor and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. Aromatase inhibitors which can be combined... Agent: Millen, White, Zelano & Branigan, P.C.

20080261930 - Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application: wherein R is H or C1-C4 alkyl; Z1 is carbonyl or β-hydroxymethylene; X1 is —O— or —S—; R5 is —OH, —OR6, —OCOOR6 or —OCOR7 wherein R6 is C1-C4 alkyl and R7 is C1-C4 alkyl, fluoromethyl or chloromethyl; and the dotted line in ring A indicates that the 1,2-linkage is saturated... Agent: Buchanan, Ingersoll & Rooney PC

20080261928 - Method of treating human preeclampsia employing resibufagenin: A method of treating preeclampsia including administering a therapeutically effective dose of resibufagenin to a patient having preeclampsia. Effecting the determination of the presence of preeclampsia may be by determining whether there has been a substantial elevation in marinobufagenin which may be blood-derived or urine-derived and if such elevation does... Agent: Eckert Seamans Cherin & Mellott

20080261933 - Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases: The present invention relates to the combination of the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one lutein-hormone-releasing hormone agonist or antagonist and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. Lutein-hormone-releasing hormone agonists... Agent: Millen, White, Zelano & Branigan, P.C.

20080261934 - Dosage form for hormonal contraception: A dosage form for hormonal contraception containing a specific number of gestagen-containing daily units A and a specific number of gestagen-containing daily units B for uninterrupted, daily, oral administration of daily units A and then immediately subsequently of daily units B, wherein the daily units A in each case contain... Agent: Crowell & Moring LLP Intellectual Property Group

20080261931 - Method and means of preventing and treating sleep disordered breathing: A method of treating or preventing snoring, obstructive sleep apnea (OSA) and/or central sleep apnea (CSA) comprises administering a pharmacologically effective amount a salt of acetylhomotaurine (AcHT) such as calcium acamprosate (CA) to a patient. Also disclosed is the use of AcHT and CA for the manufacture of a medicament... Agent: Dickstein Shapiro LLP

20080261932 - Methods and compositions for the prevention and/or treatment of an exacerbation of asthma: m

20080261935 - 2\" oxo-voruscharin and derivatives thereof: Compounds and pharmaceutical compositions which include 2″ oxo-voruscharin and derivatives are disclosed. The compounds and pharmaceutical compositions are useful in methods of treating cancer, particularly pancreatic cancer.... Agent: Knobbe Martens Olson & Bear LLP

20080261936 - Methods of reducing the body weight of a subject by administering a fatty acid ester of an estrogen or estrogen derivative in an oil and compositions containing the same: Compositions and methods for reducing the body weight of a subject are disclosed. The invention is directed to methods for reducing the body weight in a subject comprising administering therapeutically effective amounts of a fatty acid ester of an estrogen or estrogen derivative in an oil. Furthermore the invention is... Agent: Jones Day

20080261937 - Pharmaceutical compositions and method for treating pediatric hypogonadism: The present invention relates to compositions for treating prepubertal males of adolescent age with insufficient testosterone production using a hydroalcoholic testosterone gel formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of treating said adolescent males.... Agent: Mayer Brown LLP

20080261938 - Tetracyclic indole derivatives as antiviral agents: The present invention relates to tetracyclic indole compounds of formula (I); wherein R1, R2, R14, R15, A, Ar, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.... Agent: Merck And Co., Inc

20080261939 - Stannsoporfin compositions and administration: Pharmaceutical compositions including stannsoporfin, drug products incorporating pharmaceutical compositions, methods of making pharmaceutical compositions, and methods of treating hyperbilirubinemia with drug products and compositions are disclosed.... Agent: Morrison & Foerster LLP

20080261942 - Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications: The present invention provides compositions, therapeutic combinations and methods including: (a) at least one bile acid sequestrant; and (b) at least one substituted azetidinone or substituted β-lactam sterol absorption inhibitor which can be useful for treating vascular conditions, diabetes, obesity and lowering plasma levels of sterols.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080261941 - Biaryl ether urea compounds: e

20080261940 - N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides: The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R1-R5 are described in the description, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.... Agent: Pharmacia & Upjohn

20080261945 - Compounds having activity at nk3 receptor and uses thereof in medicine: wherein R1 is phenyl optionally substituted by 1, 2 or 3 halogen atoms which halogen atoms may be the same or different; R2 is C1-6alkyl, C3-6cycloalkyl or acetyl; X is oxygen or sulphur; a is 1, 2 or 3; b is 0 or 1; c is 0, 1 or 2;... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080261947 - Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient: Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc.), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc.), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal... Agent: Sughrue Mion, PLLC

20080261944 - Indole derivatives as antiviral agents: The present invention relates to indole compounds of the formula (I): wherein R1, R2, R3, R4, A, E and X are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections.... Agent: Merck And Co., Inc

20080261946 - Pyrimidine compounds for the treatment of inflammatory disorders: The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds.... Agent: Nixon Peabody, LLP

20080261943 - Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use: or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of... Agent: Cooper & Dunham, LLP

20080261948 - Ligands for g-protein coupled receptors: The invention also provides methods of preparing the compounds, pharmaceutical compositions comprising the compounds and use of the compounds for the preparation of medicaments intended to modulate the activity of one or more members of the G-protein coupled receptor (GPCR) class. Compounds of the invention may be used to create... Agent: Schwegman, Lundberg & Woessner, P.A.

20080261949 - Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same: in which R represents a hydrogen or halogen atom, an —S(O)z(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —SO2NH(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl group or an —NHSO2phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C1-C4)alkyl group or with a (C1-C4)alkoxy group; R1 represents a hydrogen atom or a... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080261950 - Compounds that inhibit cholinesterase: Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The compounds of the invention are employed in methods to treat an individual. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a cholinergic deficiency and conditions or... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080261951 - Condensed azepines as vasopressin agonists: This invention provides novel compounds according to general formula (1) wherein A is a bicyclic or tricyclic azepine derivative, V1 and V2 are both H, OMe or F, or one of V1 and V2 is Br, Cl, F, OH, OMe, OBn, OPh, O-acyl, N3, NH2, NHBn or NH-acyl and the... Agent: Foley And Lardner LLP Suite 500

20080261952 - Aryl urea derivatives for treating obesity: A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.... Agent: Osi Pharmaceuticals, Inc.

20080261954 - Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment: The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally... Agent: Knobbe Martens Olson & Bear LLP

20080261953 - Compounds, compositions and methods of inhibiting alpha-synuclein toxicity: Compounds and compositions are provided for treatment or amelioration of one or more symptoms of α-synuclein toxicity, α-synuclein mediated diseases or diseases in which α-synuclein fibrils are a symptom or cause of the disease. In one embodiment, the compounds for use in the compositions and methods are heteroaryl acylguanidines, heteroarylhydrazones,... Agent: Fish & Richardson P.C.

20080261955 - Use of pharmaceutical compositions of lofepramine for the treatment of adhd, cfs, fm and depression: In accordance with the present invention, it has been discovered that compounds exhibiting activity as a potent noradrenaline reuptake inhibitor (e.g., a NA:5HT ratio of greater than or equal to about 1000:1), and activity at the dopamine D2 receptor sites (e.g., lofepramine) are effective in the treatment and prevention of... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20080261956 - Substituted phenols as active agents inhibiting vegf production: The present invention relates to methods, compounds, and compositions for inhibiting angiogenesis. More particularly, the present invention relates to methods, compounds, and compositions for inhibiting VEGF production.... Agent: Hoffmann & Baron, LLP

20080261957 - Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives: e

20080261958 - Combination of organic compounds: The present invention relates to a combination comprising: (a) an angiotensin II receptor blocker (ARB), or a pharmaceutically acceptable salt thereof; (b) a calcium channel blocker (CCB), or a pharmaceutically acceptable salt thereof; and (c) one of the two active agents selected from (i) a rennin inhibitor, or a pharmaceutically... Agent: Novartis Corporate Intellectual Property

20080261959 - Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-y)-n-pentanoyl-n[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine: This invention relates to novel crystalline forms of valsartan, namely Form A, Form B, Form C, Form D and their solvates thereof. Processes for the preparation of the novel forms are also provided. The present invention further relates to novel processes for preparing a stable amorphous form of valsartan, and... Agent: Blank Rome LLP

20080261960 - Biologically active methylene blue derivatives: The compounds are biologically active photosensitisers which are strongly photocytotoxic and have application in the areas of photodynamic therapy (PDT), as well as for the diagnosis and detection of medical conditions and related uses in photochemical internalisation, in the production of cancer vaccines, in the treatment and prevention of microbial... Agent: Nixon & Vanderhye, PC

20080261961 - Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases: Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma,... Agent: Hovey Williams LLP

20080261962 - Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators: The invention is directed to a method for alleviating respiratory depression in a subject as a result of disease of pharmacological agents such as opiates, opioids or barbiturates. The invention also discloses pharmaceutical compositions for use with the method, the composition containing in combination, an analgesic, anaesthetic, or a sedative... Agent: Townsend And Townsend And Crew, LLP

20080261963 - Substituted quinobenzoxazine analogs: e

20080261964 - Substituted quinolones ii: The invention relates to substituted quinolones of formula (I) and to methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, in particular against cytomegaloviruses.... Agent: Morrison & Foerster LLP

20080261965 - Kinase inhibitors useful for the treatment of myleoprolific diseases and other proliferative diseases: Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant, melanomas, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, leukemias, papillary thyroid carcinoma,... Agent: Hovey Williams LLP

20080261966 - Bis-aryl sulfonamides: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.... Agent: Brinks Hofer Gilson & Lione

20080261967 - Modulators of central nervous system neurotransmitters: Disclosed are agents having pharmacological activity against cellular receptors and intracellular signaling, particularly receptors and signaling pathways of central nervous system (CNS) neurotransmitters. Also disclosed are related methods and compositions for the treatment or prevention of diseases or disorders using the agents.... Agent: Jones Day

20080261969 - 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them: s

20080261968 - Heterobicyclic metalloprotease inhibitors: The present invention relates generally to azabicyclic containing pharmaceutical agents, and in particular, to azabicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azabicyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, which exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and... Agent: Amgen Inc.

20080261970 - Sufonamides and uses thereof: Compounds of formula (I), including methods of making and methods of using are described in formula (I).... Agent: Fish & Richardson PC

20080261971 - Novel heterocyclic nf-kb inhibitors: The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, (I) wherein R1 is independently hydrogen, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl or substituted arylalkyl; R2 is independently —NR3R4, (II) or (III) R3 is independently alkyl,... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080261972 - Cgrp receptor antagonists: Compounds of Formula (I), (where variables R1, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also... Agent: Merck And Co., Inc

20080261973 - Sulphonamidoaniline derivatives being janus kinase inhibitors: wherein A is N or CH, W, X, Y and Z are N or CH under the proviso that at least one of the three symbols W, X and Y represent CH, R1 represents NR4R5 or OR4, wherein R4 represents optionally substituted alkyl, optionally substituted cycloalkyl optionally comprising one or... Agent: Novartis Institutes For Biomedical Research, Inc.

20080261974 - Novel chemical compounds: This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080261975 - Tec kinase inhibitors: wherein Q, R1, R2, R3, R4 and R5 are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080261976 - Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same: as well as their salts with inorganic or organic acids, their solvates and/or their hydrates, which exhibit a very high affinity both for the human NK2 receptors for neurokinin A and for the human NK3 receptors for neurokinin B and are antagonists of the said receptors. The invention also relates... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080261978 - Chemokine receptor modulators:

20080261977 - Pyrimidine derivatives as cannabinoid receptor modulators: The present invention relates to novel pyrimidine derivatives such as compounds of the formula (I) and the use of such compounds or pharmaceutical compositions thereof in the treatment of diseases, particularly pain, which are mediated by the activity of the cannabinoid 2 receptor.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080261979 - Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals: e

20080261980 - Use of thiazolidinone derivatives as antiangiogenic agents: The invention relates to the use of compounds of general formula (I), in which R1, R2 and X are as defined in the description for the preparation of pharmaceutical compositions for the treatment of pathologies in which inhibition of the interaction between HIF-1α and p300 is beneficial, in particular as... Agent: Seed Intellectual Property Law Group PLLC

20080261981 - Novel derivatives of amino acids for treatment of obesity and related disorders: Novel amino acid derivatives are provided that are useful for management of disorders such as obesity and immunological diseases. The derivatives are also useful in lowering blood glucose levels in hyperglycemic disorders and for treating related disorders such as body weight gain, elevated free fatty acid, cholesterol and triglyceride levels... Agent: Beyer Weaver LLP

20080261982 - Stilbene derivatives as new cancer therapeutic agents: Stilbene derivatives exhibit killing and suppression of growth activity against a variety of cancer cells, and are effective at suppressing tumor growth in vivo. The stilbene derivatives may be used in the treatment of diseases characterized by cell hyperproliferation including human malignancies and non-malignant diseases such as liver cirrhosis. Stilbenes... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080261983 - Substituted morpholinyl compounds: This disclosure relates to novel substituted morpholinyl compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a 5HT4... Agent: Fish & Richardson P.C.

20080261984 - Use of s,s-reboxetine in the treatment of pain: Use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pain condition selected from neuropathic pain, nociceptive pain, cancer pain, back pain, inflammatory pain, musculo-skeletal disorders, visceral pain, pain from strains/sprains, post-operative pain, posttraumatic pain, burns, renal... Agent: Pharmacia Corporation Global Patent Department

20080261986 - Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug: Pharmaceutical formulations suitable for iontophoresis thereof that provide enhanced iontophoretic delivery of an anti-fungal drug to at least one body surface are described. Also described are pharmaceutical formulations suitable for iontophoresis comprising terbinafine and methods for administering terbinafine to a body surface via iontophoresis. In one embodiment, the body surface... Agent: Elmore Patent Law Group, PC

20080261985 - Synthesis and biological activities of new tricyclic-bis-enones (tbes): This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-γ,... Agent: Fulbright & Jaworski L.L.P.

20080261987 - Substituted piperazines: Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated... Agent: Townsend And Townsend And Crew, LLP

20080261988 - Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors: m

20080261989 - Quinoxaline inhibitors of the hedgehog signalling: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I wherein A is a carbocycle or heterocycle; X is alkylene, NR4C(O), NR4C(S), NR4C(NH), NR4SO, NR4SO2, NR4C(O)NH, NR4C(S)NH, C(O)NR4, C(S)NR4, C(NH)NR4, NR4PO or NR4PO(OH) wherein... Agent: Millen, White, Zelano & Branigan, P.C.

20080261990 - Novel pyrimidine derivatives and their use: The present invention relates to novel pyrimidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular diseases, in particular dyslipidemias, arteriosclerosis,... Agent: Barbara A. Shimei Director, Patents & Licensing

20080261991 - Reducing side effects of tramadol: The invention provides methods of reducing the side effects of tramadol. Accordingly, in one embodiment, the invention provides a method of reducing the incidence of newly-discovered side effects related to sexual function in human males taking a tramadol material. The method comprises administering a phosphodiesterase inhibitor to a male taking... Agent: Sheridan Ross PC

20080261992 - Pyridin-2-one compounds and their use as modulators of the dopamine d3 receptor: e

20080261994 - Cyclopropane compounds and pharmaceutical use thereof: wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080261993 - Insecticidal 3-(dihaloalkenyl) phenyl derivatives: Certain novel 3-(dihaloalkenyl)phenyl derivatives have unexpected insecticidal activity. These compounds are represented by formula (I), where R through R5, a, b, D, E, G and U are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula (I), and optionally, an effective... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080261995 - Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor: This invention relates to the combined use of a PDE5 inhibitor and a 5-alpha reductase antagonist in the treatment of lower urinary tract symptoms (LUTS), such as urgency, frequency, nocturia and urge incontinence.... Agent: Pfizer Inc.

20080261996 - Substituted propiolic acid amides and their use for producing drugs: The present invention relates to substituted propiolic acid amides, methods for the production thereof, medicaments containing these compounds and the use thereof for producing medicaments.... Agent: Norris, Mclaughlin & Marcus, Pa

20080261997 - Use of aminoindazole derivatives for the inhibition of tau phosphorylation: R5, R6 and R7 are, independently of one another, chosen from the following radicals: halogen, CN, NO2, NH2, OH, OR8, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, —O—SO2R8, —SO2—O—R8, trifluoromethyl, trifluoromethoxy, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080261998 - Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors: The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080261999 - Azabicycloalkane derivatives useful as nicotinic acetylcholine receptor agonists: Compounds of the formula I or a pharmaceutically acceptable salt thereof: processes for their preparation, pharmaceutical compositions which contain them and their uses in therapy.... Agent: Eli Lilly & Company

20080262000 - 5-alkoxyalkyl-6-alkyl-7-aminoazolopyrimidines, process for their preparation, their use for controlling harmful fungi, and compositions comprising them: m

20080262001 - Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection: The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A2A adenosine receptors (ARs).... Agent: Williams Mullen

20080262003 - Methods for treating neoplasia with combination of chemotherapeutic agents and radiation: e

20080262002 - Use of s-adenosylmethionine, vitamin e, and vitamin c for the treatment of oxidative liver injury or insulin resistance: The present invention provides antioxidant compositions comprising S-adenosylmethionine (SAMe), vitamin E and vitamin C and uses thereof for the treatment of liver injury and insulin resistance.... Agent: Merchant & Gould PC

20080262004 - Tgf-beta inhibitors: The present invention is directed to inhibitors of TGF-β of Formula I:... Agent: Eli Lilly & Company

20080262006 - Selective endothelin type-a antagonists: This invention relates to novel endothelin receptor antagonists that selectively inhibit the interaction between Endothelin-1 (ET-1) and endothelin type-A receptors, their derivatives, acceptable acid addition salts. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080262005 - Uracil-type gonadotropin-releasing hormone receptor antagonists and methods related thereto: Compounds having utility as GnRH receptor antagonists and for treatment of a variety of sex-hormone related conditions in both men and women. Such compounds have the following structure (I): (I) wherein R1a, R1b, R1c, R2a, R2b, R3, R4, R5, R6, R7, n and X are as defined herein, including stereoisomers,... Agent: Seed Intellectual Property Law Group PLLC

20080262008 - Crystalline forms and polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as succinate salts: in the form of pharmaceutically acceptable salts and polymorphs thereof. The present invention is directed to methods for preparing and manufacturing crystalline polymorphs or forms of specific anilino-pyrimidine benzenesulfonamide compounds. Methods for converting one crystalline form or polymorph of compounds of formula I as their pharmaceutically acceptable salt polymorph to... Agent: Wyeth Patent Law Group

20080262009 - Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as acetate salts:

20080262010 - Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as d-glucoronate salts:

20080262007 - Hiv inhibiting 5-substituted pyrimidines:

20080262011 - Modulator: The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof. Formula (I), wherein R1 and R2 are each independently H or alkyl; Y is an alkyl group. CONR3R4, COOR5SO2NR16R17, NHSO2R18 or CN; X is an aryl or heteroaryl group, each of which may be... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080262012 - Pharmaceutical compositions comprising polymorphic forms alpha, beta, and gamma of rifaximin: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the... Agent: Biotechnology Law Group C/o Portfolioip

20080262013 - Oxymorphone controlled release formulations: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.... Agent: Mayer Brown LLP

20080262014 - Use of camptothecin derivatives for the treatment of proliferative diseases in a fixed dosing regimen: Topoisomerase I inhibitors are administered for the treatment of proliferative diseases according to a once every three day fixed dosing regimens. Furthermore, the invention provides the use of topoisomerase inhibitors to manufacture a medicament which can be used in a fixed dose treatment regimen.... Agent: Novartis Corporate Intellectual Property

20080262016 - Isoquinoline derivatives and methods of use thereof: The invention provides novel classes of Isoquinoline Derivatives. Pharmaceutical compositions and methods of making and using the compounds, are also described.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080262015 - Aryl imidazoles and their use as anti-cancer agents: Therapeutically effective 2,4,5-trisubstituted imidazole compounds are provided. Also provided are methods -of preparing the compounds and pharmaceutical compositions comprising the compounds alone or in combination with other agents. The present invention further provides for the use of the compounds as anti-cancer agents; wherein: R1 is aryl, substituted aryl, heterocycle, substituted... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080262017 - Sugar-free storage-stable antihistaminic syrups: New and improved storage-stable sugar-free antihistaminic syrups are disclosed.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080262018 - Treating allergic and inflammatory conditions: A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080262020 - 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof: m

20080262019 - Optical isomers of (+) and (-)-trans-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1h-pyrido[4,3-b] indole: The present invention represents novel optical isomers produced according the invention that are optic antipodes to each other having individual biological activity which can be used as active ingredients in pharmaceutical compositions with nootropic and sedative activity for treatment of different individual conditions of patients.... Agent: Morgan & Finnegan, L.L.P.

20080262021 - 1h-imidazoquinoline derivatives as prote in kinase inhibitors: The invention relates to imidazoquinolines of formula (I) for use in the treatment of protein kinase dependent diseases; pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease; novel imidazoquinolines; and a process for the preparation of the novel imidazoquinolines.... Agent: Novartis Corporate Intellectual Property

20080262022 - Method of treating actinic keratosis: A method of treating actinic keratosis including applying topically to an actinic keratosis lesion twice per week for a duration of 8 weeks a formulation comprising 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine.... Agent: Edwards Angell Palmer & Dodge LLP

20080262023 - Aminomethyl azaadamantane derivatives and methods of use thereof: The invention relates to compounds that are substituted aminomethyl azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20080262024 - Rifaximin compositions and method of use: Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use.... Agent: Biotechnology Law Group C/o Portfolioip

20080262027 - Novel chemical compounds: This invention relates to newly identified compounds for inhibiting YAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of YAK3 proteins.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080262025 - Processes for the preparation of zolpidem and its hemitartrate: The invention relates to the preparation of a non-hygroscopic polymorphic form of zolpidem hemitartrate, designated as Form I, and pharmaceutical compositions including it. The invention also relates to use of the compositions for treating anxiety, sleep disorders and convulsions. The invention also relates to a process for the preparation of... Agent: Ranbaxy Inc.

20080262026 - Therapeutic agents 684: Certain 4,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one and 4,5-dihydropyrrolo[3,2-c]pyridin-4-one compounds of formula I, processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, methods for their therapeutic use and pharmaceutical compositions containing them are described.... Agent: Morgan Lewis & Bockius LLP

20080262028 - Imidazole derivatives as inhibitors of tafia: or any stereoisomeric form of the compound of the formula I or a mixture of these forms in any ratio or a physiologically acceptable salt of the compound of the formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), and to a process for their preparation and to... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080262029 - Acid and base salt forms of gaboxadol: The present invention is directed to novel acid salt forms and base salt forms of the compound gabaoxadol (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol) and hydrates, solvates and polymorphic forms thereof. The invention is further concerned with pharmaceutical compositions containing the salt forms as an active ingredient, methods for treatment of disorders susceptible to amelioration... Agent: Darby & Darby P.C.

20080262030 - Organic compounds: e

20080262031 - 4-aminoquinoline derivatives as antimalarials: New 4-aminoquinoline derivatives having the general formula (I) wherein R, M, X, Y and T have the meaning described in the specification, as potent antimalarials active also on chloroquine-resistant Plasmodium falciparum malaria strains.... Agent: Schneck & Schneck

20080262032 - Isoxazoline derivative and novel process for its preparation: The present invention relates to an isoxazoline derivative having the cyclic carboxylic acid hemiketal moiety of formula (1) for use as caspase inhibitor, a process for preparing it, and a pharmaceutical composition comprising it.... Agent: Birch Stewart Kolasch & Birch

20080262033 - 4-phenyl-5-oxo-1,4,5,6,7,8- hexahydroquinoline derivatives as medicaments for the treatment of infertility: The present invention- relates to 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives having the general Formula (I) wherein the substituents are defined as in the description, or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives in therapy, more... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20080262034 - Lipoic acid derivatives: Lipoic acid derivatives and pharmaceutical formulations containing lipoic acid derivatives are useful in the treatment and prevention of disease characterized by disease cells that are sensitive to lipoic acid derivatives.... Agent: Fitzpatrick Cella Harper & Scinto

20080262035 - Amide derivatives as inhibitors of histone deacetylase: The present invention relates to carboxylic acid derivatives that are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.... Agent: Merck And Co., Inc

20080262036 - Phenyl-[1,2,4]-oxadiazol-5-one derivatives, pharmaceutical compositions and therapeutic use thereof: wherein the R1-R10 and B, U, V, W, X, Y and Z substituents are defined herein. The claimed invention also comprises the compounds isomers and their physiologically acceptable salts as well as processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080262037 - Piperidine derivatives for the treatment of chemokine mediated disease: The present invention provides a compound of a formula (I) wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.... Agent: Fish & Richardson P.C.

20080262038 - Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof: Compounds of Formula: wherein R1, R2, and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080262039 - Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions: m

20080262040 - Chemical compounds: where R1 and R2 are as defined below. These compounds are useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, in particular in the treatment and prevention of disorders mediated by IKK2 mechanisms including inflammatory and tissue repair disorders. Such disorders include rheumatoid arthritis,... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080262041 - Beta-lactams for treatment of cns disorders: e

20080262042 - Pyrrole compounds: wherein R1 is an optionally substituted cyclic group, R2 is a substituent, R3 is an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a halogen atom, a cyano group or a nitro group, R4 and R5 are each a hydrogen atom,... Agent: Edwards Angell Palmer & Dodge LLP

20080262043 - Solid crystalline form of pantoprazole free acid, salts derived therefrom and process for their preparation: The invention relates, in general, to a new solid crystalline form of pantoprazole free acid (denominated “Form III”), salts derived therefrom (e.g., pantoprazole sodium and pantoprazole sodium sesquihydrate) and methods for producing the same. The invention further includes formulating pantoprazole free acid Form III, salts derived therefrom (e.g., pantoprazole sodium... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20080262045 - Metalloproteinase inhibitors: e

20080262044 - Pesticidal mixtures: The present invention relates to a synergistically effective pesticidal composition which comprises, on the one hand, a bisamide and, on the other hand, known fungicidal active ingredients and which is accordingly very well suited to controlling undesirable animal pests such as insects and acarids and also undesirable phytopathogenic fungi.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080262046 - Amidopropoxyphenyl orexin receptor antagonists: The present invention is directed to amidopropoxyphenyl compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent: Merck And Co., Inc

20080262047 - Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients: e

20080262048 - Control of parasites in animals by the use of novel trifluoromethanesulfonanilide oxime ether derivatives: Novel trifluoromethanesulfonanilide oxime ether compounds useful for controlling endo and/or ectoparasites in the environment are provided, together with methods of making the same, and methods of using the inventive compounds to treat parasite infestations in vivo or ex vivo.... Agent: Intervet/schering-plough Animal Health Patent Department

20080262049 - Therapeutic agent for hematopoietic tumor: [wherein, n represents an integer of 1 to 3, R1 represents a hydrogen atom, R2 represents lower alkyl, or R1 and R2 are combined together to represent alkylene, R3 represents lower alkyl, R4 represents NHSO2R6 (wherein R6 represents hydroxy or the like) or the like, and R5 represents aryl or... Agent: Greenblum & Bernstein, P.L.C

20080262050 - Organic compounds: are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. The compounds of... Agent: Novartis Corporate Intellectual Property

20080262052 - Methods for the treatment of metabolic and glucose utilization disorders through the administration of oxadiazolones and derivatives thereof as peroxisome proliferator - activated receptor (ppar) delta agonists: in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved; neurodegenerative diseases and/or... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080262051 - Triazole derivatives which are smo antagonists:

20080262053 - Use of pramipexole for treating moderate to severe restless legs syndrome (rls): The invention relates to the use of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole, the (+)- or (−)-enantiomer thereof or the pharmacologically acceptable salts thereof for treating moderate to severe Restless Legs Syndrome (RLS).... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080262054 - Pharmaceutical composition containing thiazolidinedione compound: e

20080262055 - Macrocyclic acyl guanidines as beta-secretase inhibitors: wherein R1, R2, R3, R4, R5, n and X as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the... Agent: Louis J. Wille Bristol-myers Squibb Company

20080262056 - Oxindole oxazolidinones as antibacterial agents: The present invention relates to novel oxazolidinones derivatives of oxindoles of formula I or a pharmaceutically acceptable salt thereof wherein: Y1 is CH or CF; R1 is —C1-4alkyl, optionally substituted with a fluoro atom, or R1 is —C3-5cycloalkyl; and R2 is —C1-2alkyl. These compounds are useful as antibacterial agents.... Agent: Pfizer Inc Steve T. Zelson

20080262057 - Diarylisoxazolines: The invention disclosed in this document is related to field of pesticides and their use in controlling pests.... Agent: Dow Agrosciences LLC

20080262058 - Macrocylic inhibitors of hepatitis c virus: e

20080262059 - Methods of treatment and pharmaceutical composition: selected from the group consisting of hypertension, heart failure, such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency... Agent: Novartis Corporate Intellectual Property

20080262061 - Composition and use of a liquid fungicidal formulation of myclobutanil or tebuconazole fungicide: A fungicide composition containing a fungicide compound and a surfactant, wherein the fungicide is fully dissolved in the surfactant, and wherein the fungicide is selected from either myclobutanil or tebuconazole or a mixture thereof.... Agent: Connolly Bove Lodge & Hutz LLP

20080262060 - Crystalline forms of deferasirox: The present invention provides novel crystalline forms of deferasirox, methods for their production, and methods for conversion of the novel forms to the known crystalline form I.... Agent: Kenyon & Kenyon LLP

20080262062 - Method of treating diseases with parp inhibitors: The present invention discloses various diseases that have up-regulated or down-regulated PARP and can be treated with PARP inhibitors or PARP activators, respectively. The examples of the diseases include cancer, inflammation, metabolic disease, CVS disease, CNS disease, disorder of hematolymphoid system, disorder of endocrine and neuroendocrine, disorder of urinary tract,... Agent: Wilson Sonsini Goodrich & Rosati

20080262063 - Novel inhibitors of glutaminyl cyclase: e

20080262064 - Novel compounds for the treatment of gi disorders 682: The present invention relates to novel imidazole compounds having a positive allosteric GABAB receptor (CUR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux... Agent: Pepper Hamilton LLP

20080262065 - Novel inhibitors of glutaminyl cyclases: e

20080262066 - Azole derivatives as cannabinoid cb1 receptor antagonists: A novel azole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The prevention also provides a method for preparing same, a pharmaceutical composition containing same,... Agent: Sughrue Mion, PLLC

20080262067 - Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof: A pharmaceutical composition comprising idazoxan or derivatives and their therapeutically acceptable salts, racemates, optically active isomers and polymorphs.... Agent: Birch Stewart Kolasch & Birch

20080262068 - Method of tonic treatment with oxyphenbutazone derivatives: The present invention provides a method of tonic treatment of an aging mammalian subject, or a subject suffering from mild inflammation, lupus, fatigue, lethargy or the aftereffects of infection, disease or treatment, comprising administration of a compound of formula (I) or a salt thereof. Said compounds are also used as... Agent: Bacon & Thomas, PLLC

20080262069 - Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment: The present invention relates to carvedilol phosphate salts, which include novel crystalline forms of carvedilol dihydrogen phosphate (i.e., dihydrogen phosphate salt of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy) ethyl]amino]-2-propanol) and/or carvedilol hydrogen phosphate, etc.), and/or solvates thereof, compositions containing the aforementioned salts and/or solvates, and methods of using the aforementioned salts and/or solvates to treat... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080262070 - Pharmaceutically active tetrahydro-pyrrolizinone compounds: Tetrahydro-pyrrolizinone compounds which mediate the activity of LFA-1 with its ligands involved in cell adhesion, migration and activation.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080262071 - Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder: In accordance with the present invention, it has been discovered that pindolol provides a highly effective treatment for PMS and/or PMDD. As such, the present invention generally relates to methods and compositions for treating and/or preventing PMS, or symptoms associated therewith including premenstrual tension or premenstrual dysphoria. The methods and... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20080262072 - Compositions and kits comprising a melatonin component and a flavanol component: Disclosed herein are compositions and kits, wherein each composition comprises a melatonin component, a flavanol component, or both, and wherein each kit comprises a melatonin component and a flavanol component. The compositions and kits are useful for restorative sleep function and enhanced energy. Further disclosed herein are methods of using... Agent: The Procter & Gamble Company Global Legal Department - Ip

20080262073 - pyrrolic derivatives with histone deacetylase inhibitory activity: The invention describes new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases.... Agent: Ostrolenk Faber Gerb & Soffen

20080262074 - Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-(phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid or solvates or hydrates thereof, as well as crystalline salts characterized by their X-ray powder diffraction pattern are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic... Agent: Pfizer Inc.

20080262075 - Pyrrolidine derivatives as muscarinic receptor antagonists: This invention relates to pyrrolidine derivatives, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Processes for the preparation of described compounds, pharmaceutical compositions containing the described compounds and the methods for treating the diseases mediated... Agent: Ranbaxy Inc.

20080262076 - Novel tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain: i

20080262077 - Pharmaceutical formulations containing lipoic acid derivatives: Pharmaceutical formulations containing lipoic acid derivatives are made.... Agent: Fitzpatrick Cella Harper & Scinto

20080262078 - Pharmaceutical compositions: The present invention relates to a process for the preparation of a stable lyophilized form of a water insoluble drug suitable for parenteral use and pharmaceutical compositions comprising such lyophilized form of the drug.... Agent: Pharmaceutical Patent Attorneys, LLC

20080262079 - Cannabinoid compositions and methods of use thereof: The present invention provides cannabinoid compositions and the use of such cannabinoid compositions in the treatment of autoimmune and/or inflammatory diseases and disorders. For example, the present invention provides a method of using tetrahydrocannabinoid (THC) compounds in the treatment of autoimmune and/or inflammatory diseases and disorders.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080262080 - Allergy suppressive agent: Namely, it is intended to provide an allergy suppressive agent comprising chrysin, more specifically speaking, a histamine release inhibitory agent comprising chrysin; a composition comprising chrysin that is a composition for treating a disease or condition relating to the production of IgE; a composition comprising chrysin that is a composition... Agent: Birch Stewart Kolasch & Birch

20080262081 - Novel use of nutraceutical compositions comprising resveratrol: The use of resveratrol, a derivative, metabolite or analogue thereof, in combination with at least one additional component selected from EGCG, coenzyme Q-IO, genistein, lycopene, hydroxytyrosol and polyunsaturated fatty acids in the manufacture of a nutraceutical composition for delaying aging and/or for the treatment or prevention of age-related diseases in... Agent: Nixon & Vanderhye, PC

20080262082 - Composition containing s-(-)-tulipalin b or acetylated-s-(-)-tulipalin b: The present invention provides S-(−)-tulipalin B, acetylated-S-(−)-tulipalin B and an antibacterial composition comprising the same. The active compound tulipalin B and composition of the present invention exhibit superior and stable antibacterial activity over a broad range of temperature and pH, as compared to conventional natural antibacterial agents used in related... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080262083 - Antibacterial agents: D-(threo)-1-aryl-2-disubstitutedacylamido-3-fluoro-1-propanol compounds compounds and analogues thereof (“Fenicol Compounds”), compositions comprising an effective amount of a Fenicol Compound, and methods for treating or preventing a bacterial infection in an animal comprising administering to an animal in need thereof an effective amount of a Fenicol Compound are disclosed.... Agent: Townsend And Townsend And Crew, LLP

20080262084 - Stable emulsion compositions for intravenous administration having preservatie efficacy: Monoglycerides, especially Monolaurin, are used to protect intravenously administrable oil-in-water emulsion compositions against growth of E. coli, P. aeruginosa S. aureus and C. albicans. The compositions can be medicaments containing lipophilic drugs, especially Propofol, and/or total intravenous nutritional compositions.... Agent: Thorpe North & Western, LLP.

20080262085 - Method for restructuring keratin fibers: The invention relates to a method for restructuring keratin fibers during which a keratin fiber is brought into contact with cystine and with at least one dicarboxylic acid having 2 to 10 carbon atoms. The invention also relates to preparations for use in this method.... Agent: Jeffer, Mangels, Butler & Marmaro, LLP

20080262086 - Substituted anthranilic acids: Disclosed herein are substituted anthranilic acids, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of hypertension, edema associated with congestive heart failure, hepatic disease, renal disease including nephrotic syndrome, or clearance of toxic substances from the body.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080262087 - T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds: s

20080262088 - Methods, compounds, and compositions for treating metabolic disorders and diabetes: Disclosed herein are methods, compounds and compositions for preventing or treating a pancreatic disorder, including diabetes mellitus (e.g. type 1 and/or type 2 diabetes). The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to... Agent: Millen, White, Zelano & Branigan PC

20080262089 - Process for the preparation of tamsulosin: The invention includes an improved process for producing tamsulosin comprising reacting 5-(2-aminopropyl)-2-methoxybenzenesulfonamide with 2-(o-ethoxyphenoxy)ethyl bromide in an organic phosphite solvent to obtain tamsulosin. Optically pure (R)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide can be employed to produce optically pure (R)-tamsulosin product. The organic phosphite solvent utilized in the reaction can include tri-alkyl phosphites such as triethyl... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20080262090 - Guanylhydrazone salts, compositions, processes of making, and methods of using: The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their use.... Agent: Law Office Of John K. Pike, PLLC

20080262091 - Infiltration of capsaicin into surgical sites and open wounds: The present invention provides compositions and methods for attenuating or relieving pain at a site in a human or animal in need thereof by infiltrating at a surgical site or open wound in a human or animal a dose of capsaicinoid in an amount effective to denervate the surgical site... Agent: Davidson, Davidson & Kappel, LLC

20080262092 - Regulation of osteopontin: The present invention provides methods for the regulation of osteopontin activity in a subject as well as for treating or preventing conditions associated with an increased activity of osteopontin activity in a subject.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080262093 - Methods and compositions for treating obesity: The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject. The present invention also relates to the use of PGC-1 expression levels to determine the safe dosage range for known or putative respiration uncoupling agents for use as anti-obesity therapeutics. The present... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080262095 - Protectant for uv-induced skin damage: The present invention provides a method for protecting against UV radiation-induced skin damage. Specifically, compositions including dapsone are administered to provide UV protection. The dapsone compositions may be administered orally, or by other parenteral routes, such as topically, transdermally, by inhalation, and the like.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080262094 - Treatment of comorbid premature ejaculation and erectile dysfunction: The invention provides a method of treating comorbid premature ejaculation and erectile dysfunction. In particular, the method comprises administering an effective amount of a tramadol material and an effective amount of a phosphodiesterase inhibitor. The invention also provides a pharmaceutical composition comprising a pharmaceutically-acceptable carrier, a tramadol material and a... Agent: Sheridan Ross PC

20080262096 - Squaric acid derivatives: Novel squaric acid compounds of the formula (I), in which R, R1, R1′, R2 and X have the meanings indicated in Claim (1), are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular... Agent: Millen, White, Zelano & Branigan, P.C.

20080262098 - Composition for destroying thread algae: A composition of alkali carbonate peroxyhydrate in a quantity of 45 to 85% by weight relative to a total amount of the composition and an alkali hydrogen carbonate is provided for combating pathogenic germs and parasites in water of aquaculture, ponds, and aquariums; for destroying thread algae in water; for... Agent: Gudrun E. Huckett Draudt

20080262097 - Formulations: An antimicrobial formulation containing (a) a peroxide selected from the group consisting of diacyl peroxides, alkyl hydroperoxides and metal peroxides and (b) a benzoquinone or hydroquinone. The formulation may in particular be used against staphylococci or propionibacteria, more particularly to treat skin and skin structure conditions such as acne.... Agent: Beyer Weaver LLP

20080262099 - Inhibition of tumour cell migration: The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration.... Agent: Wolf Greenfield & Sacks, P.C.

20080262100 - Method of preparing carrier liquids: The invention provides a method for the preparation of a carrier liquid which comprises the steps of: (I) preparing an emulsion comprising: a) an aqueous phase, b) A second liquid phase which is volatile and which is immiscible with aqueous phase (a), c) A carrier material which is soluble in... Agent: Unilever Patent Group

20080262101 - Method to prepare a personal care composition from a base composition and a method to prepare the base composition: A base composition is provided which comprises water and a non-ionic surfactant mixture. The base composition is suitable for use in preparing a personal care product.... Agent: Unilever Patent Group

20080262102 - Hydrophilic/hydrophobic polymer networks based on poly(caprolactone fumarate), poly(ethylene glycol fumarate), and copolymers thereof: Improved methods for preparing polyethylene glycol fumarate) are disclosed. Methods for chemically crosslinking or photocross-linking hydrophilic polyethylene glycol fumarate) with hydrophobic polymers such as poly(propylene fumarate) (PPF) and poly(caprolactone fumarate) (PCLF) to form various hydrogels (FIG. 1) with controllable hydrophilicity are also disclosed. The hydrogels are useful in the fabrication... Agent: Quarles & Brady LLP

20080262104 - Aqueous polyvinyl acetate dispersions having high shearing stability: Processes comprising: providing a monomer composition comprising a vinyl acetate monomer component and second monomer component comprising an additional monomer selected from the group consisting of acrylic acid, methacrylic acid and mixtures thereof in an amount of 0.05 to 5% by weight, wherein the vinyl acetate monomer component and the... Agent: Connolly Bove Lodge & Hutz, LLP

20080262103 - Clear oil-in-water emulsions: This invention relates to clear oil-in-water emulsions with an electrosteric surfactant, their preparation and their use in personal care products.... Agent: Philip S. Johnson Johnson & Johnson

20080262105 - 1-vinylpyrrolidin-2-one/ester copolymers: The present invention refers to segment copolymers comprising segments “A” having polyvinylpyrrolidone (PVP) structure and segments “B” having a polyester 5 structure and the process for their preparation and their use.... Agent: Jay S. Cinamon Abelman, Frayne & Schwab

20080262106 - Direct compressible trehalose solids: The present invention relates to direct compressible crystalline or semi-crystalline trehalose solids having a crystal form selected from the group consisting of trehalose dihydrate and mixtures of trehalose dihydrate and anhydrous trehalose, and having a specific surface area of at least 0.25 m2/g and products or tablets containing these. A... Agent: Fish & Richardson P.C.

20080262107 - Pharmaceutical compositions with enhanced performance: Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.... Agent: Chernoff, Vilhauer, Mcclung & Stenzel

20080262108 - Method: The invention provides methods of screening test compounds for their ability to reduce retention of atherogenic lipoproteins in atherogenesis by measuring their activity as a modulator of the binding affinity of CEL (Carboxyl Ester Lipase) to various receptors. The invention further provides methods for the use of active modulators of... Agent: Fulbright & Jaworski L.L.P.

20080262109 - Method for producing liquid preparations having a solid body content: A method for producing a liquid preparation having a solid body content and the resulting liquid preparation. According to the method, the addition of at least a portion of the solid bodies takes place only (a) in the last stage of the method preceding the pouring of the liquid preparation... Agent: Paul & Paul

20080255028 - Collagen receptor i-domain binding modulators: The present invention relates to a refined and detailed molecular model of the α2⊕1 integrin I-domain, especially the MIDAS and to the use of such a model for designing novel integrin modulators, especially α2β1 integrin modulators. The present invention further relates to novel α2β1 I-domain modulators, which are of therapeutic... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080255026 - Glycopegylated factor ix: The present invention provides conjugates between Factor Ix and PEG moieties. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar... Agent: Morgan, Lewis & Bockius LLP (sf)

20080255029 - Neuroendocrine tumor treatment: A method for treating endocrine tumors by administration of an mTOR inhibitor, optionally in combination with another drug.... Agent: Novartis Corporate Intellectual Property

20080255025 - Protease inhibition: Proteins including engineered sequences which inhibit proteases are disclosed, including proteins having two or more engineered Kunitz domains, and uses of such proteins.... Agent: Lowrie, Lando & Anastasi, LLP

20080255027 - Purification of proteins: The present invention relates to a selectively soluble polymer capable of binding to a desired biomolecules in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set... Agent: Nields & Lemack

20080255030 - Compositions and methods for the modulation of jnk proteins: The invention provides compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase 1 (JNK1 protein.... Agent: Mcdermott Will & Emery

20080255031 - Method for enhancing insulin secretion: The invention is directed to methods for enhancing endogenous insulin levels in a patient in need thereof which method comprises administering to the patient an insulin secretion-enhancing amount of racemic ranolazine or the R- or S-enantiomer of ranolazine. It is also directed to methods of treatment comprising racemic ranolazine or... Agent: Cv Therapeutics, Inc.

20080255033 - Metallopeptide gamma-melanocyte stimulating hormone compounds: Metallopeptides with a sequence of a biologically active gamma-melanocyte stimulating hormone sequence of length n residues, wherein a residue including a nitrogen atom and sulfur atom each available for complexation to a metal ion is inserted at any position from between the two and three position to the C-terminus side... Agent: Palatin Technologies, Inc.

20080255032 - Methods and compositions for preventing and treating aging or photodamaged skin: Disclosed are methods for treating aging and photodamaged skin employing topical application of compositions which comprise at least one peptide manganese complex. Also disclosed are methods wherein the composition further comprises retinol, at least one retinol derivative, or a mixture thereof and methods wherein the composition further comprises active agents... Agent: Seed Intellectual Property Law Group PLLC

20080255035 - Sparc and methods of use thereof: The invention provides methods of treating a mammalian tumors comprising combination therapy with SPARC polypeptides, an angiogenesis inhibitor and paclitaxel. The invention provides also methods of treating a mammalian tumors comprising combination therapy with SPARC polypeptides and paclitaxel. Further, the invention produces kits and methods to predict therapy responses.... Agent: Leydig Voit & Mayer, Ltd

20080255034 - Transdermal delivery system for treating infertility: The transdermal delivery system for treating infertility in a patient comprises an apparatus (10) for facilitating transdermal delivery of a drug (5a) through an area of the apparatus (10) comprises an ablator that is configured to generate a microporation in the area of the skin of the patient, and comprises... Agent: Fish & Associates, PC Robert D. Fish

20080255036 - Substituted thiophenes: Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080255037 - Endoparasiticidal compositions: The present invention relates to compositions for external application which comprise emodepside and praziquantel or epsiprantel and 1,2-isopropylideneglycerol, to their preparation and to their use for controlling endoparasites.... Agent: Bayer Healthcare LLC

20080255038 - Pharmaceutical compositions: e

20080255042 - Casr antagonist:

20080255049 - Combined use of ultrasound and growth factors to stimulate bone formation: The combination of low intensity pulsed ultrasound with administration of an osteogenic protein or proteins or their genes enhances bone repair in mammals. This combination avoids thermal activation of tissue repair mechanisms and allows the osteogenic protein or proteins or their genes to act at the site of bone fracture... Agent: Barnes & Thornburg LLP

20080255040 - Glycosylation of peptides via o-linked glycosylation sequences: The present invention provides sequon polypeptides with an amino acid sequence including one or more exogenous O-linked glycosylation sequence of the invention. In addition, the present invention provides methods of making polypeptide conjugates as well as methods of using such conjugates and their pharmaceutical compositions. The invention further provides libraries... Agent: Morgan, Lewis & Bockius LLP (sf)

20080255043 - Human lung surfactant protein, sp-d, modulates eosinophil activation and survival and enhances phagocytosis of apoptotic bosinophils: The present invention provides the use of formulation with surfactant protein-D (SP-D) in the modulation of activity of human eosinophils derived from hypereosinophilic patients to an increased activation state and increased apoptosis. Accordingly the utility of the invention can be extended in human subjects in resolution of eosinophilic inflammations in... Agent: Ladas & Parry LLP

20080255039 - Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonists/antagonists activity: The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor α-chain. Two IL-15 regions are involved in the formation of this epitope: the first region (44LLELQVISL52, peptide 1) corresponds to a sequence located in the B helix... Agent: Birch Stewart Kolasch & Birch

20080255047 - Method of treating acute renal failure with thrombomobulin variant: The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin. In conjunction with standard of care, soluble thrombomodulin will reduce tissue injury and subsequent morbidity and mortality.... Agent: Eli Lilly & Company

20080255050 - Method of treating atherosclerosis: A method of treating atherosclerosis in a subject is carried out by administering the subject 2-aminopurine or a pharmaceutically salt thereof in a treatment effective amount. Optionally, the subject may also be administered an additional hypolipidemic agent. Compositions useful for carrying out the present invention are also described.... Agent: Myers Bigel Sibley & Sajovec

20080255044 - Method of treatment: The present invention relates generally to a method of treatment and in particular a method of treating disorders of the nervous system such as arising from or during disease or injury. The method of the present invention involves manipulating expression of Eph receptors or their functional equivalents to increase or... Agent: Foley And Lardner LLP Suite 500

20080255045 - Modified fgf-21 polypeptides and their uses: Modified FGF-21 polypeptides and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080255051 - Novel peptides that promote lipid efflux: Disclosed herein are peptides with domains that promote lipid efflux from cells and optionally possess at least one anti-inflammatory domain or a domain that stimulates LCAT activity. Provided herein are methods of using the peptides to treat or inhibit diseases including dyslipidemic disorders, stroke and myocardial infarction. Also provided are... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080255048 - Pharmaceutical composition: The present invention provides oral pharmaceutical compositions that enable the successful delivery of drugs in a pharmaceutically effective amount, particularly poly (amino acids) such as peptides, peptidomimetics and proteins, e.g. hormones to a subject via oral administration to accomplish the desired therapeutic effect. The oral pharmaceutical composition comprising a poly... Agent: Novartis Corporate Intellectual Property

20080255041 - Treatment of annulus fibrosis defects: Compositions and methods for treating an annulus fibrosis defect comprising an angiogenic factor and a carrier. Methods include administering the composition to the annulus fibrosis defect, where the administering can include injecting the composition. The present compositions can stimulate angiogenesis and revascularization thereby facilitating repair of the defect.... Agent: Harness, Dickey & Pierce, P.L.C

20080255046 - Y2 selective receptor agonists for therapeutic interventions: The modified human PP peptides (i) [Lys4,Leu17,Ser30,Gln34]hPP, (ii) Lys4,Leu17,Thr30,Gln34]hPP; and (iii) [Lys4,Leu17,oxidised Met30,Gln34]hPP wherein “oxidised Met” may be the sulfoxide or sulfone, and certain analogues and derivativatised forms thereof as referred to in the specification, are selective agonists of the Y2 receptor relative to the Y1 and Y4 receptors, and... Agent: Banner & Witcoff, Ltd.

20080255052 - Immunologic regulation by theta defensins: The invention provides a method of inhibiting undesirable microbial contamination, invasion, or growth in an individual by administering to the individual an effective amount of a theta defensin. The invention additionally provides a method of inhibiting deleterious effects resulting from microbial contamination, invasion, or growth in an individual by administering... Agent: Mcdermott, Will & Emery

20080255053 - Method for the therapeutic management of endometriosis: The present inventions provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to another aspect of the present invention, the short term LH-RH treatment is... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20080255054 - Sterile suspensions of slightly soluble basic peptide complexes and pharmaceutical formulations containing them: The invention provides sterile suspensions and sterile lyophilizates of slightly soluble basic peptide complexes, and pharmaceutical formulations comprising them. The provided sterile suspensions, sterile lyophilizates and pharmaceutical formulations comprising them are particularly suitable for use in a parenteral dosage form as medicaments for the treatment and prophylaxis of diseases and... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080255055 - Use of derivatives of dipeptides for the manufacture of of a medicament for the treamtent of microbial infections: The invention relates to compositions comprising a compound based on the general formula (I) R1-Arg-R2—NH—CH(R3)—CH2—NH—R4 (I) The composition may be used to eliminate and/or reduce microorganisms such as bacteria, viruses, fungi and protozoa.... Agent: Merchant & Gould PC

20080255056 - Salts of isophosphoramide mustard and analogs thereof: e

20080255057 - Prodrug substituted benzoxazoles as estrogenic agents:

20080255058 - Composition for oral cavity: (wherein, R represents a substituted or unsubstituted, linear or branched alkyl group having from 6 to 18 carbon atoms, G represents a galactose residue, m stands for an integer of from 0 to 200, and n stands for an integer of from 1 to 30); and a coaggregation inhibitor of... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080255059 - Regulators of the hedgehog pathway, compositions and uses related thereto: The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.... Agent: Ropes & Gray LLP

20080255060 - Ester linked macrolides useful for the treatment of microbial infections: e

20080255061 - Use of phthalide derivatives: Disclosed a class of phthalide derivatives and the use of which to manufacture the sensitizer or reverser of the antineoplastic agent. The phthalide derivatives according to the invention can enhance the sensitivity of drug-resistance tumor cells against chemotherapy and decrease the drug-resistance of tumor cells 5-30 folder and enhance notably... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080255062 - Axon regeneration from adult sensory neurons: A method for rapidly screening small molecules to identify small molecules that stimulate axon regeneration and outgrowth from adult sensory neurons. The method generally comprises preparing a purified individualized dorsal root ganglia cell suspension (DRG), coating well surfaces of a suitably prepared multi-well microplate with the DRG, then dispensing dosages... Agent: Fasken Martineau Dumoulin, LLP

20080255063 - 3-b-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof: The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.... Agent: Connolly Bove Lodge & Hutz LLP

20080255066 - Antisense oligonucleotide strategies for the enhancement of cancer therapies: Effective combinations of antisense agents directed against thymidylate synthase mRNA are provided for use in cancer therapies. Combinations of antisense agents have enhanced activity compared to the activity of the individual antisense agents when used alone. The combinations may be used in conjunction with one or more chemotherapeutic agents to... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080255064 - Methods for modulating cholecystokinin expression: The invention provides a method for upregulating cholecystokinin (CCK) expression in mammalian pancreatic islets by administrating a CCK upregulating agent. The increased CCK expression activates islet cell proliferation triggering an increase in pancreatic β-cell mass and plasma insulin levels. Accordingly, methods to produce a replenishable supply of islet cells and... Agent: Quarles & Brady LLP

20080255065 - Small interfering rna molecules against ribonucleotide reductase and uses thereof: Small interfering RNA (siRNA) molecules that target a mammalian ribonucleotide reductase gene, and which are capable of inhibiting the expression of their target gene are provided. The siRNA molecules of the invention are capable of attenuating neoplastic cell growth and/or proliferation in vitro and in vivo and, therefore, can be... Agent: Sheridan Ross PC

20080255067 - Cyanocobalamin low viscosity aqueous formulations for intranasal delivery: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7%... Agent: Jones Day

20080255068 - Chemical compound and its use: The present application relates to a novel tetrahydroquinoline derivative, to a process for its preparation, to its use on its own or in combination for treating and/or preventing diseases and to its use for preparing medicaments, in particular as an inhibitor of the cholesterol ester transfer protein (CETP) for the... Agent: Barbara A. Shimei Director, Patents & Licensing

20080255069 - Medicament for preventive and/or therapeutic treatment of bowel disease: A medicament for preventive and/or therapeutic treatment of a bowel diseases such as inflammatory bowel diseases including Crohn's disease, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.... Agent: Greenblum & Bernstein, P.L.C

20080255070 - Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps: The disclosure provides, inter alia, novel bisphosphonate compounds and methods of making and using such compounds. In certain embodiments, compounds of the invention include bisphosphonates that are capable of selectively inhibiting one or more of farnesyl diphosphate synthase (FPPS), geranylgeranyl diphosphate synthase (GGPPS), and decaprenyl pyrophosphate synthase (DPPS). In preferred... Agent: Greenlee Winner And Sullivan P C

20080255071 - Synergistic fungicidal active compound combinations: e

20080255072 - Composition for inhibition of cathepsin k: The present invention relates to the a method of inhibiting bone resorption in a mammal in need thereof with an oral pharmaceutical composition comprising a cathepsin K inhibitor, or a pharmaceutically acceptable salt thereof, or a mixture thereof, according to a continuous schedule having a dosage interval of once weekly,... Agent: Merck And Co., Inc

20080255073 - Compounds for sustained release of orally delivered drugs: Disclosed are methods for providing sustained systemic blood concentrations of orally delivered drugs. Still further, disclosed are compounds and pharmaceutical compositions that are used in such methods.... Agent: Buchanan, Ingersoll & Rooney PC

20080255074 - Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression: The invention provides for a combination comprising an amount of an SSRI, or a pharmaceutically acceptable salt or solvate thereof, and an amount of a GR antagonist, or a pharmaceutically acceptable salt or solvate thereof, optionally in association with one or more pharmaceutically acceptable carriers for use as therapy for... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20080255075 - Substituted estratriene derivatives as 17beta hsd inhibitors: Substituted estratriene compounds of formula (I) useful in therapy, especially in the treatment or inhibition of a steroid hormone dependent disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1, type 2 and/or type 3 enzyme, as well as their salts, pharmaceutical compositions containing such compounds and processes for... Agent: Crowell & Moring LLP Intellectual Property Group

20080255076 - Steroid-derived pharmaceutical compositions: The present invention relates to the use of specific steroid derivatives in the preparation of medicaments for the treatment or prevention and/or amelioration of disorders relating to pathological processes in lipid rafts.... Agent: Fulbright & Jaworski L.L.P.

20080255077 - Drug and food or drink for improving pancreatic functions: Compounds such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol which have an activity for improving pancreatic function are used as an active ingredient of a pancreas function improving drug and food or drink.... Agent: Knobbe Martens Olson & Bear LLP

20080255078 - Triphenylethylene compounds useful as selective estrogen receptor modulators: Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080255080 - Hydroquinone ansamycin formulations: Pharmaceutical compositions of hydroquinone geldanamycin analogs, and uses of such compositions, are provided.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080255079 - Therapeutic use of nefopam and analogues thereof: Nefopam or an analogue thereof is useful in the treatment of a syndrome characterized by chronic pain and fatigue.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080255081 - Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin: Free radicals and reactive oxygen species have the potential to damage a wide variety of organic molecules, typically by oxidizing certain moieties. These damaging species can, for example, be produced by an organism as a by-product of cellular respiration or by the reaction of iron(II) and peroxide. The present invention... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080255082 - Hair and/or scalp care compositions incorporating terpenoid compounds: The invention provides a hair and/or scalp care composition comprising a terpenoid compound of formula (I), (II) or (III) in which R1 to R11 are each, independently, —H, —F, —Cl, —Br, —I, —OH, lower alkyl (e.g. C1-6 alkyl) or lower alkoxy (e.g. C1-6 alkoxy).... Agent: Unilever Patent Group

20080255084 - Combination of organic compounds: e

20080255085 - Novel imidazo [4,5-b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders: and wherein A, Y, R1, R2, R3, R4 and R5 are as defined in the specification as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080255083 - New pyridone derivates with mch antagonistic activity and medicaments comprising these compounds: wherein the groups and radicals B, k, L, U, V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080255086 - Heterocyclic derivatives: wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20080255087 - Compositions and methods for the treatment of cancer: The present invention relates to the use of specific compounds related to the indolocarbazole K252a, for the preparation of pharmaceutical compositions for the treatment of various forms of cancer.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080255088 - Dibenzo[b,f][1,4]oxazapine compounds: where the variables are as defined herein, their salts and pharmaceutically acceptable compositions thereof. Methods of preparing these compounds are also described. These compounds may be used in the treatment of disorders such as schizophrenia, treatment resistant schizophrenia, bipolar disorder, psychotic depression, treatment resistant depression, schizophrenia-associated depression, treatment resistant OCD,... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080255089 - Triphenylethylene compounds useful as selective estrogen receptor modulators: Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080255090 - Ceratamines a and b, and analogues, syntheses and pharmaceutical compositions thereof: Antimitotic compounds and salts are provided in which the compound has the structure (formula (I)): wherein X and Y are substituted or unsubstituted and are selected from carbon atoms and atoms of groups 15 and 16 of the periodic table; Z is selected from N—R, O and S; U is... Agent: Arent Fox LLP

20080255091 - Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus: The invention discloses aromatic amides and sulfonates to treat or prevent type 2 diabetes mellitus (T2DM), the pathological consequences of T2DM, to inhibit amyloidosis or to prevent death of β-cells of the pancreas.... Agent: Seed Intellectual Property Law Group PLLC

20080255092 - 6-substituted-2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: R6 D R?N—R″R* where R6 is —(CrC3)alkyl-S—(C0-C3)alkyl-R10, —(C1-C3)alkyl-NR11R12, —(CrC3)alkyl-O—R13. and other substituents are as defined in the specification.... Agent: Eli Lilly & Company

20080255093 - Compositions and methods for treating obesity and related disorders: The present invention is drawn to combinations of pharmaceutical agents having similar chemical and/or pharmacological properties, wherein the combinations maximize the therapeutic effect of the drug while minimizing their adverse effects. The methods and compositions of the invention are particularly useful in the treatment of obesity and related conditions which... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080255094 - Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor: The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080255095 - Benzylamine analogues: wherein R1 is C1-C6 alkyl, amino, (C1-C6 alkyl)amino, di(C1-C6 alkyl)amino or a nitrogen-containing saturated heterocyclic; R2 and R3 are hydrogen or C1-C6 alkyl; Arom is phenyl, idenyl, napthyl, phenanthrenyl, furyl, thiolyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3 oxadiazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or quinolyl; A is... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080255097 - Methods for the treatment of substance abuse and dependence: The present invention relates to methods of and compositions for treating and relieving symptoms and disease associated with indications caused by a physiological drive to alleviate a sensation of anxiety. More specifically, the present invention relates to methods of and compositions for treating and relieving symptoms associated with substance abuse... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20080255096 - Phantom phenomena treatment: The present invention relates to a substance for the treatment of the phantom phenomena of acute tinnitus and/or phantom pain, a method for the diagnosis and for the treatment of these phantom phenomena.... Agent: Klarquist Sparkman, LLP

20080255098 - Compositions and methods for treatment of psychiatric disorders: Compositions and methods for the treatment of a unipolar depression containing betaine, and folate. Formulations for oral administration optionally also contain L-methionine.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080255100 - Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof: The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to... Agent: Wyeth/finnegan Henderson, LLP

20080255099 - Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions: The invention relates to the use of diketodithiopiperazine antibiotics, in particular chaetocin and gliotoxin, for the preparation of pharmaceutical compositions for antitumor therapy.... Agent: Seed Intellectual Property Law Group PLLC

20080255101 - Nitric oxide donating diuretic compounds, compositions and methods of use: The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or... Agent: Wilmerhale/nitromed

20080255102 - Phenylaminopropanol derivatives and methods of their use: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly... Agent: Woodcock Washburn LLP/wyeth

20080255103 - Antihistamine and anti-nausea pharmaceutical compositions for topical application: A topical pharmaceutical preparation suitable for use as an antihistamine or anti-nausea drug comprises an emu oil gel base and a therapeutic amount of promethazine.HCl. The preparation may further comprise an antioxidant. The preparation is preferably packaged as a single unit dose. A method for preparing the topical pharmaceutical preparation... Agent: Akin, Gump, Strauss, Hauer & Feld, L.L.P.

20080255104 - Nsaid compositions: The invention is directed to a composition and method for treating acute pain using a composition comprising one or more NSAID's, a metasilicate and optionally a fatty acid ester resulting in increased absorption of poorly soluble active NSAID's and increased absorption in suppressed vagal systems. The preferred composition comprises meloxicam... Agent: William J Bundren The Law Office Of William J Bundren

20080255105 - Biphenyl derivatives and their use in treating hepatitis c: e same or different and represents hydrogen or a C1-C4 alkyl group; and each Het1 and Het4 is the same or different and represents —O—, —S— or —NR′—, wherein R′ is hydrogen or a C1-C4 alkyl group, the phenyl, heteroaryl, heterocyclyl and carbocyclyl moieties in R1 and R4 being optionally... Agent: Astrazeneca R&d Boston

20080255106 - Novel 2-phenyl-imidazo[4,5-b]pyridine derivatives as inhibitors of glycogen synthase kinase for the treatment of dementia and neurodegenerative disorders: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation and new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080255107 - Fungicidal mixtures comprising n-[2-(haloalk(enyl)oxy)phenyl]carboxamides: in a synergistically effective amount, methods for controlling harmful fungi using mixtures of a compound I and at least on active compound II, the use compounds(s) I with active compounds II for preparing such mixtures, and also compositions and seeds comprising such mixtures.... Agent: Hutchison Law Group PLLC

20080255109 - Non-peptide gnrh antagonists: Compounds according to general formula 1, wherein A1-A3 are selected from A5 and A6 where A5 is either ═CR13— or ═N— and A6 is —NR14—, —O— or —S—; A4 is either a covalent bond or A5, provided that when A4 is a covalent bond one of A1-A3 must be A6... Agent: Foley And Lardner LLP Suite 500

20080255108 - Novel thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions: m

20080255110 - Imidazoquinoline derivatives as adenosine a3 receptor ligands:

20080255112 - Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Alk, Abl, BRK, Blk, BMX, CSK, c-Src, c-Raf,... Agent: Genomics Institute Of The Novartis Research Foundation

20080255111 - Tissue factor production inhibitor: A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases,... Agent: Morgan & Finnegan, L.L.P.

20080255114 - 2-aminobenzoxazole carboxamides as 5ht3 modulators: m

20080255116 - Quinoline derivatives as antibacterial agents:

20080255113 - Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity: This invention provides a compound of the formula (I): wherein Het represents a heterocyclic group having one nitrogen atom, to which B binds directly, and from 4 to 7 carbon atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting... Agent: Pfizer Inc.

20080255117 - Sulfonyltryptophanols: i

20080255115 - Thiazolidinedione derivatives as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using thiazolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20080255118 - Cyanopyrimidinones: The invention relates to novel cyanopyrimidinones, process for their preparation, and the use thereof for producing medicaments for improving perception, concentration, learning and/or memory.... Agent: Barbara A. Shimei Director, Patents & Licensing

20080255119 - Diphenyl-dihydro-imidazopyridinones: and the pharmaceutically acceptable salts and esters thereof X, R1, R2, Y1 and Y2 are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080255120 - Substituted 2,5-heterocyclic derivatives: The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:... Agent: Novartis Vaccines And Diagnostics Inc.

20080255121 - Combination drug for treating autoimmune disease: It is intended to provide a combination drug for preventing and/or treating an autoimmune disease. More specifically speaking, a combination drug for preventing and/or treating an autoimmune disease which contains a CaMKII inhibitor and a disease-modifying antirheumatic drug; a medicinal composition, a commercial package, a kit, etc. for the combination;... Agent: Sughrue Mion, PLLC

20080255122 - Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis;... Agent: Pepper Hamilton LLP

20080255123 - Novel compounds as cannabinoid receptor ligands: e

20080255124 - Chemical compounds: This invention relates to non-steroidal compounds that are modulators of androgen, glucocorticoid, mineralocorticoid, and progesterone receptors, and also to the methods for the making and use of such compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080255125 - Topically applied medicament for animals: The invention relates to pharmaceutical preparations, which are applied to the pelt or skin of animals and are then absorbed by the latter orally.... Agent: Barbara A. Shimei Director, Patents & Licensing

20080255126 - Inhibitors of post-proline cleaving proteases: Novel compounds that are inhibitors of one or most post-proline cleaving proteases, e.g. dipeptidyl peptidase IV, according to general formula (1). R1 is H or CN, X1 is O, S, CH2, CHF, CF2, CH(CH3), C(CH3)2 or CH(CN), and b is 1 or 2. G1 is H or a group according... Agent: Foley And Lardner LLP Suite 500

20080255127 - Pesticide formulations with a crystallization risk, and a method for their preparation: Pesticide formulations with a crystallization risk are provided. Also provided are methods of making and using such formulations.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080255129 - 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics: s

20080255128 - Phthalazinone derivatives:

20080255130 - Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors: The present invention discloses bicyclic nitrogen-containing heterocyclic compounds for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, oily skin conditions, metabolic syndrome, and the... Agent: Cv Therapeutics, Inc.

20080255131 - N-(heteroaryl)-1h-indole-2-carboxamide derivatives and their use as vanilloid trpv1 receptor ligands: e

20080255132 - Combination therapy comprising the use of et-743 and paclitaxel for treating cancer: Methods of treating a human body for cancer are provided. In one aspect, an effective therapeutic amount of paclitaxel is administered in combination with ET-743 in a dose range between 0.5 and 1 mg/m2. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with paclitaxel... Agent: King & Spalding

20080255133 - Inhibitors of mek: This invention concerns to N-(2-aylamino)aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.... Agent: Wilson Sonsini Goodrich & Rosati

20080255134 - Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase: The present invention provides compounds of formula (I) possessing inhibitory activity against β adrenergic receptors and phosphodiesterase (PDE), including type 3 phosphodiesterase (PDE-3). The present invention further provides pharmaceutical compositions comprising such compounds, methods of preparing such compounds, and methods of using such compounds for regulating calcium homeostasis, for treating... Agent: Seed Intellectual Property Law Group PLLC

20080255135 - Novel 1-aza-bicycloalkyl derivatives: e

20080255136 - Pyrrolidones with anti-hiv activity: The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones and compounds related to pyrrolidones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to... Agent: Genomics Institute Of The Novartis Research Foundation

20080255137 - N-biaryl and n-arylheteroaryl 2-substituted piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto: The present invention relates to certain N-biaryl and N-arylheteroaryl 2-substituted piperazine derivatives of Formula (Ia) that are modulators of the 5HT2C receptor. Accordingly, compounds of the present invention are useful for the treatment of 5HT2C receptor associated diseases or disorders, such as, obesity, Alzheimer Disease, erectile dysfunction and related disorders.... Agent: Fish & Richardson P.C.

20080255138 - Novel polymorphic form of imatinib mesylate and a process for its preparation: This invention discloses a novel stable crystal form of imatinib mesylate, designated by us as α2 Form, which is stable at room temperature and even at higher temperatures up to 120° C. and accelerated stress conditions and, freely soluble in water. This invention also discloses a pharmaceutical composition containing the... Agent: Merchant & Gould PC

20080255140 - Squaric acid derivatives as inhibitors of histone deacetylase: i

20080255139 - Use of 4- (4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms: This invention relates to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide (also known as imatinib, gleevec, glivec, cgp57148b or STI571), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of c-fms-associated diseases including; choriocarcinoma, malignant histiocytosis, embryonal carcinoma, endometrial carcinoma, brain microglial tumours, sarcoidosis, microglial cell involvement... Agent: Novartis Corporate Intellectual Property

20080255142 - Substituted piperidine derivatives as somatostatin sst1 receptor antagonists: Compound of the formula (I) wherein R1, R2, n and m are as defined in the specification. The compounds of formula (I) are somatostatin sst1 receptor antagonists.... Agent: Novartis Institutes For Biomedical Research, Inc.

20080255144 - Acylated piperidines as glycine transporter inhibitors: m

20080255143 - Inhibitors of akt activity: Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080255145 - Thiadiazole compounds and methods of use: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.... Agent: Amgen Inc.

20080255141 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors: Novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles of formula (I) that selectively modulate, regulate, and/or inhibit signal transductions mediated by certain native and/or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferation metabolic, allergic and degenerative disorders. More particularly, these compounds are potent and selective... Agent: Foley And Lardner LLP Suite 500

20080255147 - Heterocycles useful as modulators of ion channels: The present invention relates to compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20080255148 - Therapeutic agent for senile dementia: e

20080255146 - Novel physiologically active substances: (wherein, R3, R6, R7 and R21 are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition... Agent: Birch Stewart Kolasch & Birch

20080255149 - Carboxyamine compounds and methods of use thereof: The invention relates to the use of carboxyamine compounds and salts thereof in the treatment of HDAC dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.... Agent: Novartis Corporate Intellectual Property

20080255151 - N-deacetylthiocolchicine deriatives, their use and pharmaceutical formulations containing them: e

20080255150 - Novel compounds: The invention relates to substituted aryl acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.... Agent: Fish & Richardson P.C.

20080255154 - Amido compounds and their use as pharmaceuticals: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or... Agent: Fish & Richardson PC

20080255152 - Diaryl ethers as opioid receptor antagonists: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3′, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related... Agent: Eli Lilly & Company

20080255153 - New compounds: and pharmaceutically acceptable salts thereof, which are useful as inhibitors of human stearoyl-CoA desaturase (SCD). The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions in which the modulation of SCD activity is beneficial, such... Agent: Edwards Angell Palmer & Dodge LLP

20080255155 - Kinase inhibitors and uses thereof: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds, compositions and methods for the inhibition of kinase activity. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions.... Agent: Keown & Zucchero, LLP

20080255157 - 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents: This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals by promotion of microtubule polymerization. This invention further relates to a method of treating or... Agent: Wyeth Patent Law Group

20080255156 - Adenosine a2a receptor antagonists: i

20080255158 - Fungicidal mixtures: The invention relates to fungicidal mixtures containing in the form of active agents: a triazolopyrimidine derivative of formula (I) and thiophanate-methyl of formula (II) in synergistically active quantity and to a method for controlling harmful fungi by means of the mixture of the compounds I and II, thereby making it... Agent: Birch Stewart Kolasch & Birch

20080255159 - 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions: e

20080255161 - 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors: The present invention discloses 3-hydroquinazolin-4-one derivatives for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cancer, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.... Agent: Cv Therapeutics, Inc.

20080255160 - Mapk/erk kinase inhibitors: e

20080255162 - Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents: wherein R2, R4, R5, R6, R8 and J have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases, including inflammatory diseases, cardiovascular diseases, and cancers. Also provided are pharmaceutical compositions comprising one or more compounds... Agent: Pfizer Inc

20080255163 - Use of modified pyrimidine compounds to promote stem cell migration and proliferation: This invention provides cells and methods for stimulating proliferation and migration of endogenous and exogenous mammalian stem cells in vivo and in vitro. The invention provides reagents and methods for efficiently proliferating mammalian stem cells in an animal in need thereof and producing stem cells that can be re-introduced into... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080255165 - Pharmaceutical compositions of the isolated d-enantiomer of the quinazolinone derivative halofuginone: The present invention relates to pharmaceutical compositions comprising as an active ingredient an isolated, chirally pure D-enantiomer of the quinazolinone derivative halofuginone having increased therapeutic activity and decreased side effects compared to the corresponding racemic mixtures, the composition being substantially free of the L-enantiomer and useful in the treatment of... Agent: Daniel J Swirsky

20080255164 - Novel 2-aminopyrimidinone derivatives and their use: This invention relates to novel compounds having the structural formula I below: (I) and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Pepper Hamilton LLP

20080255166 - Dithiocarbamate derivatives and their use as antibacterial agents: The invention relates to the use of dithiocarbamate derivatives for the therapeutic or prophylactic treatment of infectious diseases in mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and lepra caused by mycobacteria and infectious diseases caused by staphylococci. The invention further relates to novel dithiocarbamate derivatives... Agent: Nixon & Vanderhye, PC

20080255167 - Novel 2-aminopyrimidine or 2-aminiopyridinone derivatives and their use: This invention relates to novel compounds having the structural formula I below and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Pepper Hamilton LLP

20080255168 - Methods for administering dpd inhibitors in combination with 5-fu and 5-fu prodrugs: Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU... Agent: Seed Intellectual Property Law Group PLLC

20080255171 - Combination of nilotinib with farnesyl transferase inhibitors: t

20080255170 - Process for the synthesis of rosuvastatin calcium: Present invention represents process for the preparation of HMG-CoA reductase inhibitors, in particular rosuvastatin calcium introducing L-malic acid as the source of chirality for the side chain.... Agent: Sandoz Inc

20080255172 - Pyrimidine derivatives: e

20080255169 - Sulphonamide derivatives:

20080255173 - Novel specific caspase-10 inhibitors: The invention relates to compounds of the general formula (I), and to their use as caspase-10 inhibitors, especially for the treatment of diabetic retinopathy.... Agent: Millen, White, Zelano & Branigan, P.C.

20080255174 - Hydroalcoholic extract of erythrina mulungu, pharmaceutical compositions and processes for producing these substances: The use of molecules for cholinergic and/or serotonergic system models, revealing pharmaceutical compositions comprising 11-OH-erythravine, erythravine, erythrartine, pharmaceutically acceptable isotherals, salts, byproducts and/or solvates thereof, optionally containing other erythrina byproducts, for the treatment of anxiety disorders; processes for obtaining said pharmaceutical compositions are also revealed.... Agent: Smith, Gambrell & Russell

20080255175 - Anti-cancer agents, compositions and methods of treating cancers: e

20080255176 - Quinoline derivatives: The present invention relates to novel benzo[g]quinoline derivatives, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.... Agent: Novartis Corporate Intellectual Property

20080255177 - Anti-tumor activity of cci-779 in papillary renal cell cancer: This invention provides the method or use of CCI-779 in the treatment of papillary renal cell carcinoma.... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20080255180 - 4-substituted azaadamantane derivatives and methods of use thereof: The invention relates to compounds that are 4-substituted azaadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20080255179 - Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof: The invention relates to compounds that are acetamide and carboxamide derivatives of azaadamantane, compositions comprising such compounds, and methods of using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20080255178 - Azaadamantane ester and carbamate derivatives and methods of use thereof: The invention relates to compounds that are substituted azaadamantane ester and carbamate derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20080255181 - Methods for treating podocyte-related disorders: The present invention relates to methods for treating or preventing podocyte-related diseases and disorders using compounds that modulate the calcium sensing receptor or pharmaceutical compositions comprising thereof.... Agent: Amgen Inc.

20080255182 - Certain chemical entities, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080255183 - N-[heteroarylcarbonyl]-3-thienyl-l-alanine derivatives as a5beta1 antagonists: The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases... Agent: Astrazeneca R&d Boston

20080255184 - Thienopyridine b-raf kinase inhibitors: The present invention provides thienopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080255186 - Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor: e

20080255185 - Small-molecule modulators of trp-p8 activity: Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating... Agent: Townsend And Townsend And Crew, LLP

20080255187 - 5-ht4 receptor agonist compounds: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20080255188 - Muscarinic receptor antagonists: This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions... Agent: Ranbaxy Inc.

20080255189 - Hepatitis c virus inhibitors: i

20080255190 - 8-cyanoquinolonecarboxylic acid derivative: (wherein R1 represents a C3-C6 cycloalkyl group which may have a substituent or the like; R2 represents a hydrogen atom or the like; R3 and R4 each independently represent a hydrogen atom or a C1-C6 alkyl group, or a substituted carboxyl group derived from an amino acid, a dipeptide, or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080255191 - Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors: h

20080255192 - Methods and compositions for selectin inhibition:

20080255193 - Pharmaceutical composition: A novel pharmaceutical composition comprising the NK3 receptor antagonist talnetant, povidone, mannitol and a surfactant, and a process for its preparation are disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080255194 - 1,2-benzisoxazol-3-yl compounds: This invention relates to novel 1,2-benzisoxazol-3-yl compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an antagonist of both... Agent: Fish & Richardson P.C.

20080255195 - Compounds which have activity at m1 receptor and their uses in medicine: wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one or more fluorine atoms; and R6 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080255196 - Pesticide thiazolyloxy substituted phenylamidine derivatives: The present invention relates to aryloxy substituted phenylamidine derivatives of formula (I) wherein the substituents are as in the description, their process of preparation, their use as fungicide or insecticide active agents, particularly in the form of fungicide or insecticide compositions, and methods for the control of phytopathogenic fungi or... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080255197 - Cxcr4 chemokine receptor binding compounds: wherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as... Agent: Morrison & Foerster LLP

20080255198 - Biaryloxymethylarenecarboxylic acids as glycogen synthase activator: e

20080255199 - Compounds useful for the synthesis of s- and r-omeprazole and a process for their preparation: The present invention relates to an improved method for the synthesis of the (S)- or (R)-enantiomer of omeprazole, characterized in that 2-[[(4-X-3,5-dimethylpyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole or 2-[[(4-X-3,5-dimethyl-1-ox-idopyridin-2-yl) methyl]thio]-5-methoxy-1H-benzimidazole, wherein X is a leaving group, is oxidized into the corresponding sulphoxide which is obtained as a crystalline compound. Recrystallisation of the thus obtained sulphoxide... Agent: White & Case LLP Patent Department

20080255200 - Substituted benzimidazoles: Disclosed herein are substituted benzimidazole-based proton pump modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080255201 - Ppar active compounds: Compounds are described that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ.... Agent: Foley & Lardner LLP

20080255203 - Heterocyclic compounds and their methods of use: The invention relates to heterocyclic derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions. The heterocyclic derivatives, more particularly can be substituted oxadiazole compounds and derivatives thereof.... Agent: Paul D. Yasger Abbott Laboratories

20080255202 - Phenylthioacetic acid derivatives and use thereof: The present application relates to novel phenylthioacetic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders, in particular dyslipidaemias... Agent: Bayer Health Care LLC

20080255204 - Agrochemical formulation for improving the action and plant compatibility of crop protection agents: The present invention relates to novel agrochemical formulations for treating plants, which formulations comprise, as cosolvent, propylene carbonate, and, if appropriate, further additives, to a process for preparing these formulations and to their use for treating plants and/or their habitat and for increasing the efficacy and plant compatibility of crop... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080255205 - Multi-cyclic compounds and methods of use: wherein B1, B2, B3, B4, C1, C2, ring D, L1, L2 and R1-4 are defined herein, synthetic intermediates, and pharmaceutical compositions, comprising such compounds. The compounds and compositions are capable of modulating various protein kinase receptors such as Tie-2 and Aurora and, therefore, influencing kinase related disease states and conditions.... Agent: Amgen Inc.

20080255206 - Rxr agonists and antagonists, alone or in combination with ppar ligands, in the treatment of metabolic and cardiovascular diseases: The present invention relates to the use of one or more retinoid agonists and/or antagonists comprising retinoids with selective Retinoid X Receptor (RXR) agonistic or antagonistic activity alone or in combination with one or more peroxisome proliferator activated receptor (PPAR) ligands for the manufacture of a medicament for the (preferably... Agent: Volpe And Koenig, P.C.

20080255207 - 5-thioxo-1,5-dihydro-2h-pyrrol-2-one derivatives as liver x receptor modulators: The present invention relates to certain novel compounds of the Formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α(NR1H3) and/or β(NR1H2) and in treating clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease,... Agent: Pepper Hamilton LLP

20080255208 - Fungicide pyridinyloxy substituted phenylamidine derivatives: The present invention relates to 2,5-di-substituted-4-pyridinyloxy-substituted-phenyl-amidine derivatives, notably to 2,5-dialkyl-4-pyridinyloxy-substituted-phenyl-amidine derivatives, of formula (I) in which the substituents are as in the description, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of... Agent: Womble Carlyle Sandridge & Rice, PLLC

20080255209 - Combination of a nsaid and a pde-4 inhibitor: The invention relates to the combined use of a PDE4 inhibitor and a conventional NSAID in the treatment of an inflammatory disease and/or an inflammation-associated disorder while minimizing gastrointestinal side effects, such as gastric erosions and ulcer, which are frequently associated with the use of conventional NSAIDs. A preferred PDE... Agent: Gary M. Nath The Nath Law Group

20080255211 - Oxadiazole compounds: e

20080255210 - Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA... Agent: Intrexon Corporation

20080255212 - Oxadiazolones and derivatives thereof as peroxisome proliferator - activated receptor (ppar) delta agonists: in which the R1-R7 substituents as well as the U, V, W, X Y and z radicals are as defined herein, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080255213 - Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents:

20080255214 - Novel hydroxamates as therapeutic agents: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also... Agent: Wilson Sonsini Goodrich & Rosati

20080255215 - Combinations of alkylalkanolamines and alkylbisalkanolamines for antimicrobial compositions: wherein R1 and R2 are each individually selected from the group consisting of branched and linear C4 to C16 alkyl groups and wherein R3 and R4 are each individually H or methyl. Compositions incorporating these antimicrobial formulations may include treated fluids, for example organic fluids or mixtures of organic fluids... Agent: Sughrue Mion, PLLC

20080255216 - Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1: 2,5-Diaryl-1,2,4-triazole derivatives of structural formula I are selective inhibitors of the 11&bgr;-hydroxysteroid dehydrogenase Type 1 enzyme (11&bgr;-HSD-1). The compounds are useful for the treatment of diabetes, hyperglycemia, obesity, insulin resistance, atherosclerosis, dyslipidemia, hyperlipidemia, hypertension, and Metabolic Syndrome. Also disclosed are novel compounds of structural formula II which are inhibitors of... Agent: Merck And Co., Inc

20080255217 - Preventive or therapeutic agent for cardiac dysfunction or myocardial injury caused by ischemia or ischemia reperfusion: Disclosed herein is at least a method of preventing or treating cardiac dysfunction or myocardial injury caused by ischemia or ischemia reperfusion... Agent: Cantor Colburn, LLP

20080255218 - Melanin-concentrating hormone receptor antagonists and methods of use: This invention relates generally to N-benzylamino cyclic thioureas, pharmaceutical compositions containing them, and their use as antagonists of melanin-concentrating hormone receptor (MCH receptor).... Agent: Stout, Uxa, Buyan & Mullins LLP

20080255219 - Rumen protected essential amino acids: Use of essential amino acid imines and compositions containing them as a source of rumen protected essential amino acids for ruminant animals. Preferred are histidine and methionine.... Agent: Mckee, Voorhees & Sease, P.L.C

20080255221 - Novel hydroxamates as therapeutic agents: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also... Agent: Wilson Sonsini Goodrich & Rosati

20080255220 - Therapeutic substituted gamma lactams: e

20080255222 - Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases: The present invention relates to benzsulfonamide derivatives of formula I and methods of use thereof. The benzsulfonamide derivatives of the present invention are efficient modulators of the JNK pathway. In particular the benzsulfonamide derivatives of the present invention are selective inhibitors of JNK 2 and 3.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080255223 - Treatment and prevention of benign pigmented moles (naevi) using artemisinine and the derivatives thereof: A method of treating a benign pigmented mole or a dermatomycosis. The method comprises locally applying to a subject in need thereof artemisinine and/or one or more structurally related compounds. Also disclosed is a plaster which comprises a topical formulation comprising artemisinine and/or one or more structurally related compounds.... Agent: Greenblum & Bernstein, P.L.C

20080255224 - Pharmacological treatment of psoriasis: The present invention relates generally to the prevention and treatment of psoriasis and psoriatic-related skin conditions via administration of a cannabinoid agonist, especially nabinone, either alone or in combination with other agents that possess anti-psoriatic pharmacological activity.... Agent: Katten Muchin Rosenman LLP

20080255225 - Botanical extract composition: The invention relates to a kit comprising: a first composition comprising leaves of Melissa Officinalis, or parts thereof; a second composition comprising Eleutherococcus senticosus, or parts thereof; a third composition comprising Avena sativa, or parts thereof; a fourth composition comprising Ballota Nigra, or parts thereof; a third composition comprising the... Agent: Harness, Dickey & Pierce, P.L.C

20080255227 - Novel composition and method for stabilizing the same: Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.... Agent: Sughrue Mion, PLLC

20080255226 - Stabilized anthocyanin compositions: The invention describes stabile anthocyanin compositions, methods to prepare such compositions and also methods of use of such compositions to treat various afflictions. The present invention describes unique compositions of an anthocyanin and a stabilizing compound such that the combination of the two components provides that the anthocyanin does not... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080255228 - Ascorbic acid complexes for skin care including treatment of dark skin & wrinkles: This invention relates to certain complexes of ascorbic acid and its derivatives with certain aryl alkyl ketones; said complexes having being formed via a kinetically-controlled process, and having general chemical formula (I) in FIG. 1. Said complexes can be in their various optically active or racemic forms. This invention also... Agent: Shyam K. Gupta Bioderm Research

20080255229 - Parenteral solution containing amiodarone in nndma (n,n,-dimethylacetamide): Disclosed herein are parenteral solutions containing 3-diethylaminoethoxy benzoyl-benzofurans, such as amiodarone, in a diluent NNDMA (N,N-Dimethylacetamide) useful in the treatment of cardiac arrhythmias both supraventricular, ventricular as well as, the condition of cardiac arrest.... Agent: Gildo E. Fato Law Offices Laurence M. Dunlap, Ltd.

20080255230 - Therapeutic fluoroethylcyano guanidines: s

20080255231 - Polymorphs of rivastigmine hydrogentartrate: A crystalline rivastigmine hydrogentartrate of Form II and an amorphous rivastigmine hydrogentartrate of Form III.... Agent: SynthonIPInc

20080255232 - Naphthyl derivatives as inhibitors of beta-amyloid aggregation: Compounds useful in the treatment of disorders characterized by deposits of amyloid aggregates are herein described together with pharmaceutical compounds containing the same. In particular the compounds of the present invention are those having the Formula (I) as reported below, where the radicals have the meaning indicated in the description.... Agent: Lucas & Mercanti, LLP

20080255233 - Isomeric mixtures of dinitro-octylphenyl esters and synergistic fungicidal mixtures therefrom: The present invention relates to an isomeric composition comprising isomers of dinitro-octylphenyl esters, wherein the 2,6-dinitro-4-(1-propylpentyl)phenyl ester isomer is present in an amount of less than 0.1 weight percent, based on the total weight of the isomeric composition and to synergistic fungicidal mixtures therefrom.... Agent: Dow Agrosciences LLC

20080255234 - Rumen protected lysine: Use of lysine imines and compositions containing them as a source of rumen protected lysine for ruminant animals.... Agent: Mckee, Voorhees & Sease, P.L.C

20080255235 - Infusion and injection solution of levodopa: An infusion or injection solution of Levodopa containing at least 10 mg/mL of Levodopa, or at least 5 mg/mL of Levodopa together with at least 0.5 mg/mL of at least one inhibitor of a Levodopa-metabolising enzyme is disclosed. The solution further contains a buffer, a physiologically acceptable sugar, such as... Agent: Bacon & Thomas, PLLC

20080255236 - Methods and composition comprising 2-[(3-chlorophenyl)amino] phenylacetic acid for alzheimer's disease: The present invention is directed to a method of preventing or arresting the progression of Alzheimer's disease by administering to a patient having Alzheimer's disease a composition comprising an amount of 2-[(3-chlorophenyl)amino]phenylacetic acid, or a pharmaceutically acceptable salt thereof, sufficient to elicit a prophylactic or therapeutic effect. In some embodiments,... Agent: Morgan, Lewis & Bockius LLP

20080255237 - Pesticidal composition: A pesticidal preparation comprises a pesticidal composition consisting essentially of a mixture of garlic oil and allyl isothiocyanates (AITCs) in the weight ratio of from 95:5 to 60:40. It is especially effective as a pesticide, especially against nematodes commonly found in the soil.... Agent: Norris, Mclaughlin & Marcus

20080255238 - Composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases: Disclosed herein is a composition for preventing or treating pruritic or irritant skin diseases which comprises, as a vanilloid receptor antagonist, a thiourea derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, together with a pharmaceutically acceptable carrier.... Agent: Heslin Rothenberg Farley & Mesiti PC

20080255239 - Substituted fluoroethyl ureas as alpha 2 adrenergic agents: Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.... Agent: Allergan, Inc.

20080255240 - Sulfonamide derivatives: Novel sulfon amide derivatives are chemical uncouplers useful e.g. for the treatment of obesity.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080255241 - Self-sterilized, antiseptic collagen preparations, their use and methods for producing them: A method is provided for sterilizing a collagen preparation and for production of self-sterilized, antiseptic collagen preparations. The preparations may be used for producing collagen products, such as sponges, films or gels, especially for medical and/or cosmetic purposes.... Agent: Panitch Schwarze Belisario & Nadel LLP

20080255242 - Hci polymorphs of 3-((2-(dimethylamino)methyl(cyclohex-1-yl)) phenol: A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)] phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically... Agent: Crowell & Moring LLP Intellectual Property Group

20080255243 - Stat3 as a theranostic indicator: This invention relates, e.g., to a method for predicting the response of a subject having estrogen-receptor-positive breast cancer to an inhibitor of the estrogen signaling pathway (e.g. tamoxifen), comprising measuring in a cancer sample from the subject the level of phosphorylation, compared to a baseline value, of one or more... Agent: Venable LLP

20080255244 - Cam kinase ii inhibitor improves retinoic acid therapy and inhibits the proliferation of myeloid leukemia cells: A method of treating a cancer (e.g., myeloid leukemia) in a subject in need thereof, is carried out by administering the subject a CaM kinase II (CaMK II) inhibitor. In some embodiments, the CaMK II inhibitor is administered concurrently with a retinoid. In some embodiments, the CaMK II inhibitor is... Agent: Myers Bigel Sibley & Sajovec

20080255245 - Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxystilbenes and novel stilbene derivatives and analogues: The present invention provides novel diphenyl ethene compounds and pharmaceutically-acceptable salts thereof. Also provided are methods for making the compounds of the invention as well as methods for the use thereof in the treatment of immune, inflammatory, and auto-immune diseases.... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20080255246 - Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease: The subject application relates to methods of treatment of peripheral vascular disease (PVD) as well as ischemic osteonecrosis, peritoneal ischemia, chronic ocular disease, macular degeneration, or diabetic retinopathy, comprising administering a therapeutically effective amount of a trans carotenoid. The invention also relates to the use of such carotenoids as pretreatments... Agent: Nixon & Vanderhye, PC

20080255247 - Oil-in-water emulsion and its use for the delivery of functionality: The present invention concerns an oil-in-water emulsion wherein the oil droplets of a diameter in the range of 5 nm to hundreds of micrometers exhibit a nano-sized self-assembled structurization with hydrophilic domains having a diameter size in the range of 0.5 to 200 nm, due to the presence of a... Agent: Bell, Boyd & Lloyd LLP

20080255248 - Prodrug compounds with isoleucine: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080255249 - Long-chain inulin: The invention relates to long-chain inulin and its preparation from artichoke roots, its use in foodstuffs and cosmetic preparations and foodstuffs and cosmetic preparations comprising the long-chain inulin.... Agent: Hunton & Williams LLP Intellectual Property Department

20080255250 - Compounds and compositions for delivering active agents: Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.C.

20080255251 - Stabilized body care products, household products, textiles and fabrics: Disclosed are stabilized body care products, household products, textiles and fabrics which comprise certain sterically hindered amine salt compounds. Dyed products and articles are effectively stabilized against color degradation. The products are for example skin-care products, hair-care products, dentifrices, cosmetics, laundry detergents and fabric softeners, non-detergent based fabric care products,... Agent: Joann Villamizar Ciba Corporation/patent Department

20080255253 - Animal model for prostatic stromal hyperplasia: The present invention provides an animal model for prostatic stromal hyperplasia, and a method for screening for a substance effective for preventing/treating human benign prostatic hyperplasia using the animal model. The animal model for prostatic stromal hyperplasia is produced by implanting the fetal urogenital sinus of a non-human animal under... Agent: Knobbe Martens Olson & Bear LLP

20080255252 - Infectious aetiology of prostatic disease and methods to identify causative agents: The present invention relates to a method of diagnosing, or predicting risk of, prostate disease in a subject. More particularly, the invention relates to a method of diagnosing the presence of, or the predisposition to develop, prostate disease in a subject, the method comprising analysing a test sample from the... Agent: Morrison & Foerster LLP

20080248991 - Chitosan containing solution: The invention provides a composition comprising (i) chitosan, a salt or derivative thereof or a salt of a derivative thereof, (ii) a polyol-phosphate or sugar-phosphate salt, (iii) a plasticizer, and (iv) a therapeutic agent. Typically, the composition is a solution or suspension at ambient temperature but forms a gel at... Agent: Panitch Schwarze Belisario & Nadel LLP

20080248998 - Compositions for oral adminstration of active principles requiring masking of taste: Composition intended for the oral administration of active principles with unacceptable taste, which comprises from about 15% to about 30% of organoleptically unpleasant active ingredient (principle) that is mixed with from about 60% to about 80% of an ester of glycerol or of a fatty acid, to which a wax... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080248992 - Immunokine composition and method: A composition and method for preventing HIV infection of mammalian cells. One aspect of the invention relates to an anti-immunodeficiency virus immunokine capable of binding to a cellular protein in a manner that prevents HIV infection of that cell. The compositions can include either an active bioactive polypeptide, such as... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080248994 - Methods of using deacetylase inhibitors to promote cell differentiation and regeneration: A method of enhancing progenitor cell differentiation, including enhancing myogenesis, neurogenesis, and hematopoiesis, by contacting a progenitor cell with an effective amount of a deacetylase inhibitor (DI). The progenitor cell can be part of cell culture, such as a cell culture used for in vitro or in vivo analysis of... Agent: Klarquist Sparkman, LLP

20080248993 - Modified beta thymosin peptides: A composition including an oxidized or superoxidized methionine-containing beta thymosin peptide, isoform thereof, fragment thereof, isolated R-enantiomer thereof or isolated S-enantiomer thereof, other than racemic thymosin beta 4 sulfoxide, or a modified beta thymosin peptide, isoform or fragment thereof with an amino acid substituent substituted for at least one methionine... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080248995 - Modulation of ppargamma2 gene promoter by foxo1: A method for detecting a modulator of transcription of a human PPAR gene promoter is provided, comprising contacting a candidate compound with a cell transfected with an expression vector containing a heterologous gene operably linked to a PPAR promoter and an additional expression vector containing the FOXO1 gene, and comparing... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080248996 - T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds: m

20080248997 - T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds:

20080248999 - Amylin formulations: A combined insulin and amylin and/or GLP-1 mimetic formulation has been developed wherein the pH of the insulin is decreased so that the amylin and/or GLP-1 remains soluble when mixed together with the insulin. In the preferred embodiment, a bolus insulin is administered by injection before breakfast, providing adequate bolus... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080249001 - Agents that alleviate side-effects caused by chemotherapy agents: The present invention provides improving agents of side-effects of chemotherapy agents. Though the erythroid progenitor cells decrease due to the side-effect of chemotherapy agents, such side-effect can be improved by chemotherapy agents which comprise arginine as the active ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080249000 - Method of modifying gum arabic, modified gum arabic obtained by the method, and use thereof: The present invention can provide a modified gum arabic having an excellent emulsification ability without coloration and/or unpleasant odor, by a method which has a step of making unheated gum arabic into an aqueous solution having a concentration of not higher than 50 mass %, and a step of maintaining... Agent: Kratz, Quintos & Hanson, LLP

20080249002 - Cyclosporin alkyne analogues and their pharmaceutical uses: e

20080249021 - Biologically active peptides and their use for repairing injured nerves: The present invention relates to biologically active peptides derived from the neurite outgrowth-promoting domain of laminin-1, i.e. the γ1 -chain of laminin-1. These peptides include the decapeptide RDIAEIIKDI (SEQ ID NO:1) and the truncated peptides derived therefrom comprising the biologically active domain thereof, the tripeptide KDI. The invention is directed... Agent: Birch Stewart Kolasch & Birch

20080249003 - Compounds inhibiting the binding of sap for treating osteoarthritis: Use of an agent capable of inhibiting SAP ligand binding activity or depleting SAP from the plasma of a subject for the production of a medicament for treatment or prevention of osteoarthritis in the subject.... Agent: Frommer Lawrence & Haug

20080249018 - Exendin analog formulations: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080249020 - Human growth hormone treatment methods: New methods for developing dosing formulas that allow the determination of appropriate dosage regimens for human growth hormone (hGH) compounds; methods for using such formulas to calculate individualized hGH compound dosage regimens; methods for treatment of hGH-responsive syndromes in patients using such determined regimens; systems, devices, and computer-readable media comprising... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080249012 - Increasing life span by modulation of smek: The Smek (Suppressor of mek null) gene is described and characterized. Smek acts in the stress response pathway of animals by binding to and enhancing the transcription of FOXO, thereby providing the link between the stress response pathway and the insulin/IGF-1 pathway. Given the link between both the stress response... Agent: Morrison & Foerster LLP

20080249009 - Lipoprotein-regulating medicaments: Methods and pharmaceutical compositions useful for treating obesity-related disorders using ApM-1 and related proteins.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080249010 - Method of inducing apoptosis in lymphoid cells: A two-stage, transcriptionally regulated apoptotic program has been discovered. In the first stage, IL-3 withdrawal results in transcriptional activation of the NGAL gene followed by synthesis and secretion of NGAL protein. In the second stage, secreted NGAL protein induces apoptosis in lymphoid cells by an autocrine mechanism. Based on this... Agent: Fish & Richardson PC

20080249004 - Method of modulating cell survival, differentiation and/or synaptic plasticity: The present invention relates to a method of modulating differentiation, adhesion and/or survival of the neural cell adhesion molecule (NCAM) presenting cells by providing compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM. The invention provides candidate compounds capable of modulating the interaction between... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080249014 - Method of purification of hydrophobic proteins: The present invention relates to a method for obtaining highly purified hydrophobic proteins from cells by extraction using a buffer containing a detergent and removal of said detergent by hydroxyapatite (HA) column chromatography.... Agent: Baxter Healthcare Corporation

20080249008 - Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor: The present invention is based, in part, on our discovery that EGF can be engineered to generate mutants that bind to the EGF receptor (EGFR) of a cell and that have a desirable effect on the activity of the cell. For example, the mutants can agonize the receptor (i.e., increase... Agent: Fish & Richardson PC

20080249017 - Pharmaceutical formulations of ghrh molecules: Stabilized solid and liquid pharmaceutical formulations comprising a GHRH molecules as active ingredient, and more particularly GHRH analogs including [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises an anionic surfactant and a non-reducing sugar, and has a pH of about 4.0 to about 7.5. Also disclosed is the use of... Agent: Darby & Darby P.C.

20080249006 - Pharmaceutical preparation for the treatment of shock: a

20080249007 - Protracted exendin-4 compounds: Novel protracted exendin-4 compounds and therapeutic uses thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080249019 - Treatment of mucus hypersecretion: A polypeptide and a nucleic acid encoding the polypeptide are described. The polypeptide includes a cytotoxic toxin, a targeting domain that selectively binds to a target cell that is a mucus-secreting cell and a translocating domain that translocates the cytotoxic toxin into the target cell. A nucleic acid encoding the... Agent: Morris Manning Martin LLP

20080249015 - Use of des-aspartate-angiotensin 1: The present invention generally relates to the use of des-aspartate-angiotensin I, its derivative, a functional part and/or analogue thereof in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I, its derivative, a functional part and/or analogue thereof, for the treatment and/or prophylaxis of viral infections, for... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080249005 - Use of dm43 and its fragments as matrix metalloproteinases inhibitor: This invention is related to the use of DM43 protein as a metalloproteinases inhibitor. More specifically, this invention is related to the use of DM43 for the therapeutics of pathologies such as cancer and osteoarthritis, which are dependent on matrix metalloproteinases inhibition, based on the structure identity with SVMPs.... Agent: Klarquist Sparkman, LLP

20080249016 - Use of glp-2 in a combination treatment for bone-related disorders: i

20080249011 - Use of mgc4504: The invention concerns the use of MGC4504 protein, a functional derivative or fragment thereof, or a nucleic acid coding for said protein, derivative or fragment, for the identification of substances active in preventing or treating a disease associated with or caused by a malfunction of the carbohydrate or lipid metabolism.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080249013 - Vaccines: Compositions and methods for the therapy and diagnosis of cancer, particularly lung, colon, colorectal and breast cancer, are disclosed. Illustrative compositions comprise one or more Cripto tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080249023 - Antibacterial peptide with activity against b. anthracis: Disclosed is a therapeutic peptide useful in the treatment or prevention of infection caused by Gram-positive bacteria such as Bacillus anthracis.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080249022 - Antimicrobial peptides derived from cap18: The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The... Agent: Morrison & Foerster LLP

20080249025 - Methods and means for inhibition of cdk4 activity: p21WAF1 interacts with cyclin D1 and Cdk4. Peptide fragments of p21 inhibit the interaction and/or affect Cdk4 activity. The peptides, derivative peptides and non-peptidyl mimetics thereof are useful in affecting activity of Cdk4, such as RB phosphorylation and cellular proliferation, indicative of therapeutic usefullness in treatment of tumors and other... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20080249024 - Peptides facilitating or inhibiting a nterograde transport: 1

20080249026 - Peptides and their utility in modulation of behavior of cells expressing alpha3beta1 integrins: The present invention relates to a peptide comprising the sequence R1-X1-X2-X3-X4-R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X1 is selected from the group consisting of R and K; and X4... Agent: Townsend And Townsend And Crew, LLP

20080249027 - Chec-7 a novel spla2 inhibitor and methods of use for treating neurological and inflammatory disorders: The present invention relates to the discovery of a composition including a seven-amino acid peptide that promotes neuronal survival, inhibits inflammation, and is a potent inhibitor of sPL2A, and uses thereof.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080249029 - Methods for treating skin pigmentation: This invention relates to methods and compositions for bringing about changes in skin pigmentation. More particularly, this invention relates to compounds which affect melanogenesis and can be used as depigmenting agents or as agents for darkening skin utilizing the PAR-2 pathway.... Agent: Philip S. Johnson Johnson & Johnson

20080249028 - Thyrotropin-releasing hormone analogs and method of use: The invention provides a method of modulating blood glucose levels by treating or preventing pancreas-related disorders with thyrotropin-releasing hormone (TRH) or a TRH derivative. Diabetes mellitus, pancreatic islet destruction, pancreatic beta cell malfunction, and hyperglycemia-related malfunction are preferably treated or prevented.... Agent: Edwards Angell Palmer & Dodge LLP

20080249030 - Age inhibitors: The invention relates to a compound having general formula I, wherein: X represents CH2, C═O, C═S or CHOH, X represents CH2, C═O, C═S or CHOH, R1 represents an amino acid which is optionally substituted by one or more halogen atoms, preferably fluorine, or by one or more CF3 groups and... Agent: Alston & Bird LLP

20080249031 - Crystalline forms: The present invention relates to crystalline forms of (3S)-3-[N—(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid (see formula I). The invention further relates to pharmaceutical compositions comprising such crystalline forms and to the use of said pharmaceutical compositions and said crystalline forms in the treatment of various conditions, particularly in the treatment of liver fibrosis.... Agent: Pharmacia Corporation Global Patent Department

20080249032 - Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors: Described herein are derivatives of arylsulfonamido-substituted hydroxamic acid of formula (I) having good solubility in water and inhibitory activity of matrix metalloproteinases, useful for the preparation of pharmaceutical compositions for the treatment of diseases associated to a pathologic activity and/or an over-expression of metalloproteinases, and of cosmetic preparations having anti-ageing... Agent: Jay S Cinamon Abelman Frayne And Schwab

20080249033 - Carbamate linked macrolides useful for the treatment of microbial infections: s

20080249035 - Polymorph of clarithromycin (form v): A polymorphic form of clarithromycin (form V) which exhibits a characteristic X-ray diffraction pattern, a method for producing such polymorphic clarithromycin, and the use of such polymorphic clarithromycin to treat bacterial infections.... Agent: Crowell & Moring LLP Intellectual Property Group

20080249034 - Use of macrolides for treating intestinal inflammation: The present invention relates to a compound of formula (IA) as defined in the specification or a pharmaceutically acceptable sat thereof, in the preparation of a medicament for both the treatment of inflammatory bowel diseases and the prevention of colon cancer.... Agent: Lucas & Mercanti, LLP

20080249036 - Antagonist against tolerance to anticancer drugs: An ABC transporter protein expression inhibitor comprising, as the active ingredient(s), 0.001 to 100 nM of one or more members selected from among steroid hormones, compounds having a female hormone function, analogous compounds thereof and antagonistic inhibitors therefor; an anticancer composition containing this ABC transporter protein expression inhibitor and an... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080249037 - Synthetic molecules having immune activity: The present invention is directed to synthetic molecules having biological activity similar to PIM (acyl glycerol phosphatidylinositol manno-oligosacccharide) activity, for use in the treatment and prevention of inflammatory or immune cell mediated diseases or disorders.... Agent: Knobbe Martens Olson & Bear LLP

20080249058 - Agents that reduce neuronal overexcitation: The present invention provides methods of identifying candidate agents for treating excitotoxicity-related disorders. The present invention further provides methods for treating excitotoxicity-related disorders.... Agent: Bozicevic, Field & Francis LLP

20080249042 - All-trans-retinol: all-trans-13,14-dihydroretinol saturase and methods of its use: Compositions of all-trans-retinol: all-trans-13,14-dihydroretinal saturase and methods of use thereof are provided.... Agent: Woodcock Washburn LLP

20080249051 - Antimicrobial compounds: The present invention relates to compounds that modulate the shikimate pathway and/or a pathway branching from the shikimate pathway in members of the Amoebida Order. In particular these compounds may be useful in the treatment or prevention of diseases caused or contributed to by members of the Amoebida Order.... Agent: Alston & Bird LLP

20080249038 - Bone morphogenetic protein (bmp) 2a and uses thereof: The present invention provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. In particular, some embodiments of the present invention provide one or more pharmaceutical compositions comprising as an... Agent: Cooper & Dunham, LLP

20080249053 - Compositions and methods for detecting and treating neurological conditions: The present invention relates to the NIPA-1 proteins and nucleic acids encoding the NIPA-1 proteins. The present invention further provides assays for the detection of NIPA-1 polymorphisms and mutations associated with disease states, as well as methods of screening for ligands and modulators of NIPA-1 proteins.... Agent: Casimir Jones, S.c.

20080249050 - Compounds and methods to enhance raav transduction: Agents and methods to alter rAAV transduction are provided.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20080249041 - Formulations comprising antisense nucleotides to connexins: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation... Agent: Duane Morris LLP

20080249054 - Method of measuring lipid droplets and applications of using the same: The invention relates to methods of screening agents for the ability to regulate lipid metabolism and using said agents to treat diseases or disorders related to lipid metabolism (e.g., obesity, diabetes [non-insulin and insulin dependent], hypertension, coronary artery disease, hyperlipidemia (e.g., LDL, TAGs), hypolipidemia (e.g., HDL), lipid metabolism disorders, lipid... Agent: Merchant & Gould PC

20080249048 - Methods and compositions for the treatment of intestinal conditions: Methods and compositions for the treatment of intestinal disorders, such as IBD and Crohn's disease, are disclosed. Preferred compositions include siNA. Also disclosed is a method of specifically targeting siNA to treat intestinal disorders by intrarectal administration of siNA compounds.... Agent: King & Spalding

20080249043 - Methods and compositions involving protein kinase c-delta: Disclosed are methods and compositions relating to the use of PKC-δ activators in the treatment of disease.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20080249056 - Methods of altering an immune response induced by cpg oligodeoxynucleotides: It is disclosed herein that agents that affect the activity and/or expression of CXCL16 can be used to alter the uptake of D-type CpG oligodeoxynucleotides (D ODNs). Methods of inducing an immune response are disclosed that include administering agents that increase the activity and/or expression of CXCL16 and a D... Agent: Klarquist Sparkman, LLP

20080249045 - Mgal: a gal gene switch-based suite of methods for protein analyses and protein expression in multicellular organisms and cells therefrom: The invention provides methods for detecting and analyzing protein-protein interactions and agonists and antagonists thereof, detecting and analyzing protein sequences, and regulatable gene expression in multicellular organisms or cells therefrom.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080249039 - Modified short interfering rna (modified sirna): The present invention is directed to modified siRNA which are significantly impaired in their ability to support cleavage of mRNA when incorporated into a RISC complex. Such modified siRNA may be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the modified siRNA comprises a... Agent: Edwards Angell Palmer & Dodge LLP

20080249046 - Modified sirna molecules and uses thereof: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains full RNAi activity against the target sequence. The present invention also... Agent: Townsend And Townsend And Crew, LLP

20080249047 - Modulation of inflammation through modulation of elavl1/hur expression: In the present invention modulation of expression of a member of the Elavl1/Hu family is used to modulate at least translation of specific mRNA. Inducible increase of HuR in murine innate compartments suppresses inflammatory responses in vivo. HuR over-expression induced the translational silencing of specific cytokine mRNAs, despite positive or... Agent: Hoffmann & Baron, LLP

20080249044 - Nucleic acid external skin formulation: The present invention provides a nucleic acid external skin formulation having high skin permeability, which is prepared from a polymeric nucleic acid which has high molecular weight and sodium alginate. The nucleic acid external skin formulation is highly skin permeable and delivers its active ingredient nucleic acid to the affected... Agent: Flynn Thiel Boutell & Tanis, P.C.

20080249049 - Polycationically charged polymer and the use of the same as a carrier for nucleic acid: A composition for the delivery of nucleic acid to target cells or tissues, which comprises polycationically charged polymer as a carrier of nucleic acid is provided. Said polycationically charged polymer is a polymer which may comprise a charged polymer segment having a main chain based on poly(amino acid), polysaccharide, polyester,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080249057 - Protein kinase c as a target for the treatment of respiratory syncytial virus: The subject invention concerns a method of inhibiting respiratory syncytial virus (RSV) infection in a patient by decreasing the endogenous protein kinase C (PKC) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administration of a PKC inhibitor. The present inventor has determined that... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080249040 - Rna interference mediated inhibition of sterol regulatory element binding protein 1 (srebp1) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of Sterol Regulatory Element-Binding Protein 1 (SREBP1) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits,... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080249052 - Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma: The present invention provides novel dystrophin mini/micro-genes that retain the essential biological functions of a full-length dystrophin gene. More particularly, the present invention provides to a series of synthetic mini/micro-dystrophin genes capable of restoring neuronal nitric oxide synthase (nNOS) to the sarcolemma. A method as well as a pharmaceutical composition... Agent: Scully Scott Murphy & Presser, PC

20080249055 - Use of seh inhibitors as analgesics: The present invention provides methods and compositions for relieving pain and itching, of promoting wound healing, of reducing sickness behavior and of reducing inflammatory bowel disease or acne lesions in a subject by the topical administration of an inhibitor of soluble epoxide hydrolase, or of a cis-epoxyeicosatrienoic acid (“EET”), or... Agent: Townsend And Townsend And Crew, LLP

20080249059 - Compositions and methods for modulating calcium flux, glucose homeostasis and apoptosis: Compositions and methods are disclosed which are effective for modulating glucose homeostasis, calcium ion flux and cell death in target cells.... Agent: Dann, Dorfman, Herrell & Skillman

20080249060 - Nucleoside derivatives for treating hepatitis c virus infection: Disclosed are compounds, compositions and methods for treating hepatitis C virus infections.... Agent: Genelabs Technologies, Inc. C/o Foley & Lardner LLP

20080249061 - Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis: Ophthalmic composition containing brivudine as active ingredient and a film-forming agent selected from the group consisting of polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA) and polyacrylate (PA).... Agent: Arent Fox LLP

20080249064 - Activities of an active principle obtained from powdered alfalfa seeds (medicago sativa), active principle used and process of obtaining the same: The object of the invention is an active principle derived from a powder of alfalfa seeds (Medicago sativa) permitting counteracting, in a manner similar to retinol, the phenomenon of extrinsic aging of the skin, with anti-wrinkle and smoothing properties. The invention also covers the active principle, the procedure of obtaining... Agent: Young & Thompson

20080249063 - Composition for promoting the maintenance and function of muscle-specific progenitor cells: The biological function of skeletal muscle precursor cells in the repair and growth of skeletal muscle in response to exercise is promoted by providing a supplemental composition comprising at least creatine and fucoidin to reinforce biochemical pathways involved in the maintenance of skeletal muscle satellite cells and other myogenic precursors.... Agent: Iovate Health Science Research Inc.

20080249062 - Nucleus pulposus filler: The present invention provides a nucleus pulposus filler or the like which is to be packed into an area in deformed intervertebral disc wherein normal nucleus should be located and can be stabley maintained for a long time. More preferably, the present invention provides a nucleus pulposus filler comprising a... Agent: Sughrue-265550

20080249065 - Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate: This invention relates to ophthalmic wound-healing pharmaceutical compositions based on amino acids and sodium hyaluronate.... Agent: Steinfl & Bruno

20080249066 - Antiviral compounds and compositions: Described herein are compounds useful in the treatment of viral diseases, compositions comprising them and methods of using them. The compounds comprise a nucleoside or nucleoside analog linked, commonly through a phosphate group to one of a selected group of lipids. In some embodiments, the compounds described herein are useful... Agent: Wilson Sonsini Goodrich & Rosati

20080249067 - Organophosphorous compounds for the activation of gamma/delta t cells: s

20080249068 - Method of extending the dose range of vitamin d compounds: Inhibitors of bone calcium resorption are administered, and calcium intake in the subject's diet is restricted, to allow high doses of vitamin D compounds or mimetics to be given with the intent of treating diseases such as metabolic bone diseases, hyperparathyroidism, cancer, psoriasis, and autoimmune diseases without the dangers of... Agent: Andrus, Sceales, Starke & Sawall, LLP

20080249069 - Method of treatment using bisphosphonic acid: The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080249070 - Cycloalkane-containing sphingosine 1-phospate agonists: The present invention provides sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P1 receptor type. The compounds invention include compounds having a phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha-substituted phosphonates, and phosphothionates.... Agent: Iplm Group, P.A.

20080249071 - Inflammatory cytokine release inhibitor: e

20080249072 - Use of low dose chemically modified tetracylines to reduce inflammatory mediators: The invention is a method for reducing the production of inflammatory mediators, and/or treating conditions characterized by increased levels of inflammatory mediators, in a mammal in need thereof, by administering a 4-dedimethlaminosancycline to the mammal.... Agent: Ronald J Baron Hoffmann & Baron

20080249073 - Skin treatment composition: e

20080249074 - Composition for the transdermal administration of physiologically active agents: Improved composition for the administration of a physiologically active agent through the skin which comprises at least one vegetable oil, oleic acid, and at least one lactone of a saturated or unsaturated fatty acid of 5 to 22 carbon atoms, said two last components acting as absorption enhancers. Using said... Agent: Berenbaum, Weinshienk & Eason, P.c

20080249075 - C11 modified retrosteroids as progesterone receptor modulator compounds: Retrosteroidal compounds corresponding to formula I, representing progesterone receptor modulators, and their production, and pharmaceutical preparations containing these compounds. These compounds are useful in the treatment of benign gynecological disorders such as endometriosis and uterine fibroids, as well as for female birth control and for hormone replacement therapy.... Agent: Crowell & Moring LLP Intellectual Property Group

20080249076 - Pharmaceutical compositions comprising danazol: A controlled release pharmaceutical comprising danazol has the property of slow release of danazol over an extended period of time and markedly increased bioavailability compared to commercially available danazol-containing products. The pharmaceutical composition comprises danazol dissolved in a solid vehicle or carrier and is especially suitable for oral solid dosage... Agent: Darby & Darby P.C.

20080249077 - 17.beta.-fluoromethoxycarbonyl-androst-4-en-3-one compounds with a 17.alpha.-carbonate sustituent: c

20080249078 - Method and use of nanoparticles to bind biocides in paints: This invention relates to the use of a combination of selected substances in paint to prevent the settlement and growth of different biofouling organisms with a reduced negative effect on the ecosystems compared to present methods.... Agent: Lynn E Barber

20080249079 - Pyrimidine derivatives as kinase modulators and method of use: The invention provides compounds and methods for inhibition of kinases, more specifically IGF 1 R kinases. The invention also provides compounds and methods for inhibition of wildtype Abl. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080249080 - Benzodiazepine derivatives and uses thereof on medical field: e

20080249081 - Compounds for the treatment of pain and screening methods therefor: Disclosed herein are benzoimidazole compounds; pharmaceutical compositions comprising a therapeutically effective amount of the same; methods of modulating the activity of an MrgX1 or an MrgX2 receptor using the same; and methods of alleviating acute, chronic and neuropathic pain in a subject using the same. Also disclosed are methods of... Agent: Biotechnology Law Group C/o Portfolioip

20080249082 - Use of memantine (namenda) to treat autism, compulsivity and impulsivity: The present invention relates to the treatment of compulsive, impulsive and pervasive developmental disorders. More particularly, the methods described herein comprise administration of memantine to an individual suffering from such a disorder in an amount effective to relieve one or more symptoms of said disorder. In particularly preferred aspects, the... Agent: Marshall, Gerstein & Borun LLP

20080249083 - Novel genes related to glutaminyl cyclase: Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl... Agent: Sonnenschein Nath & Rosenthal LLP

20080249084 - Triazole compounds and uses related thereto: The present invention provides a triazole compound of the following formula: a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound is useful as a therapeutic drug for the treatment of diabetes, obesity or metabolic syndrome.... Agent: Foley And Lardner LLP Suite 500

20080249085 - Maytansinoid analogs as antitumor agents: Ansamycin analogs, including maytansinoid analogs, and their use in treating cell proliferative diseases and conditions, and in particular, for use as antitumor agents.... Agent: Calfee Halter & Griswold, LLP

20080249087 - Heterocylic antiviral compounds: This invention relates to piperidine derivatives of formula I wherein R1, R2, R3 and R4 are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080249086 - Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias: There is provided compounds of formula I, wherein R1, R2, R4, R41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.... Agent: Pepper Hamilton LLP

20080249088 - Topical delivery of antifungal drugs: A topical formula for treatment of antifungal infections of the skin and nails comprises: (a) a therapeutically effective amount of a benzylamine or morpholine antifungal compound; (b) an aliphatic alcohol substituted with an aromatic substituent in which the antifungal compound is soluble to a degree that a therapeutically effective concentration... Agent: William L Sherrett

20080249089 - 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions: t

20080249090 - Substituted pyridone compounds and methods of use:

20080249091 - Indoles useful in the treatment of inflammation: wherein X1, R1, R2, R3, R4, R5 and R6 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment... Agent: Morgan Lewis & Bockius LLP

20080249092 - Novel quinoline compounds capable of binding at the cb2 receptor: e

20080249093 - (3,4-disubstituted)propanoic carboxylates as sip (edg) receptor agonists: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of... Agent: Merck And Co., Inc

20080249094 - Compounds for the treatment of neurodegenerative disorders: wherein R3, R5, R7, U, X, Y and Z are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. This invention also relates to pharmaceutical compositions and methods of treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula... Agent: Pfizer Inc

20080249095 - 1-acyldihydropyrazole derivatives: Compounds of the formula (I), in which R1, R2, R3a, R3b, R3c and R3d have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20080249096 - Pharmaceutical forms with improved pharmacokinetic properties: The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and lead to increased bioavailability and to a plateau-like plasma concentration profile, and to processes for their preparation.... Agent: Barbara A. Shimei Director, Patents & Licensing

20080249097 - Prodrugs of heteroaryl compounds: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.... Agent: Townsend And Townsend And Crew, LLP

20080249098 - 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use: R1 represents a hydrogen atom or a (C1-C4)alkyl group; R2 and R3 each represent, independently of one another, a hydrogen atom or a (C1-C4)alkyl group or else R2 and R3 form, with the nitrogen atom which carries them, a pyrrolidinyl, piperidinyl, morpholinyl or 4-alkylpiperazinyl group; and Het represents a heteroaromatic... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080249099 - 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors:

20080249101 - Benzoimidazole, tetrahydro-quinoxaline, benzotriazole, dihydro-imidazo[4,5-c] pyridinone and dihydro-isoindolone derivatives: wherein A, R1 to R3 are as defined in the specification and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridine and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080249100 - Pteridinone derivatives for use as stearoyl coa desaturase inhibitors: e

20080249102 - Hiv protease inhibitors:

20080249103 - Sirtuin polymorphisms and methods of use thereof: Provided herein are methods for diagnosis and prognosis using polymorphic variants of sirtuins. Such polymorphic may be used, for example, to identify subjects that would be responsive to treatment with a sirtuin modulating compound and/or subjects that are suffering from or susceptible to a disease mediated by a sirtuin. Also... Agent: Ropes & Gray LLP

20080249104 - Salt forms of 4- (4-methylpiperazin-1-ylmethyl) -n- [4-methyl-3- (4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl]- benzamide: The present invention relates to acid addition salts of 4-[(4-methyl-1-piperazinyl)methyl]-N-(4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, which are selected from the group consisting of a tartrate salt, such as a (D)(−) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, a fumarate salt, a succinate salt, a benzoate salt,... Agent: Novartis Corporate Intellectual Property

20080249105 -